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1. Introduciton 
The term cancer, which is derived from the Greek word "karkinos", meaning crab, 
encompasses over 100 distinct diseases that are characterized by an uncontrolled 
multiplication of abnormal cells. The oldest written description of cancer known to exist 
dates back to about 1600 BC, but is believed to be based on a much earlier document, from 
ca. 3000 BC. It is part of the Edwin Smith Papyrus, and describes eight cases of breast 
tumors or ulcers in Egypt and their treatment by cauterization. Signs of cancer can also be 
traced back as far as 3000 BC, on the bones of mummies from ancient Egypt and Peru. 
Humans, though, must have fought against this pathology throughout their existence, for 
which, according to the above-mentioned papyrus, there was no cure (American Cancer 
Society, 2010). This opinion was shared by the Greek physician Hippocrates (about 400 BC), 
known today as the “Father of Medicine”, who believed that it was best to leave cancer 
alone, as those who received treatment did not survive long. Hippocrates claimed that 
cancer was due to an excess of black bile, one of the four fluids (or humors) that, according 
to the humoral theory that he developed, composed the body. Hippocrates was the first to 
use the words carcinos and carcinoma to describe non-ulcer forming and ulcer-forming 
tumors, probably to reflect similarities between certain aspects of the tumors’ appearance 
and that of crabs (Feinberg et al., 2006). In the first century BC, the Roman physician Celsus 
translated the Greek term into cancer, the Latin word for crab. Later, in the second century 
AD, Galen, another Roman physician, used the Greek word oncos (meaning swelling) to 
describe tumors.  
From ancient times, cancer never failed to attract the attention of the medical community, 
leading to advances in several areas, most notably in the surgical removal of tumors. 
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Interest in oncology clearly intensified in the eighteenth century, leading to arguably the 
first true experiments in cancer research, namely the inoculation of a dog with cancer fluid 
from humans, reported by Bernard Peyrilhe, in 1774 (Triolo, 1965). 
The multiple theories to explain neoplasia that accompanied the ever-increasing interest in 
oncological research were, almost inevitably, in line with the more general pathological 
theories of the time (Triolo, 1965). Accordingly, the vast majority of them have since fallen 
out of fashion. Understandably, the genetic basis of cancer, a cornerstone of modern cancer 
research, could only begin to unravel after the discovery of the chromosomes, those rod-like 
structures (mitosen) that formed from the nucleus fibrous network in the dividing nucleus, 
as observed by Walther Flemming, an acknowledged master of microscopy, during his 
landmark comprehensive investigation into cell division (Flemming, 1882). As the nuclear 
network could be easily stained, Flemming named it chromatin (i.e., stainable material), 
designating its metamorphosis as mitosis (from the Greek word for thread). In 1888, the term 
chromosome was finally coined, by Wilhelm Waldeyer (from chroma and soma, the Greek 
words for colored and body, respectively) (Waldeyer, 1888). Flemming's description of 
chromosomes was accompanied by a detailed account of the sequence of their movements 
during cell division, deduced from his many observations of cells in various stages of 
division (Flemming, 1882). He assumed that the chromosomes were longitudinally split 
during mitosis, the two halves partitioning into the two daughter cells at the end of the 
process. This account, which was confirmed, decades later, by microscopy of live dividing 
cells, is considered as a founding moment in genetic research. Likely unaware of Gregor 
Mendel's speculative work on heredity, which was published in an obscure journal in 1865 
(Mendel, 1866), Flemming did not make a connection between the distribution of nuclear 
material during cell division and genetic inheritance. Nonetheless, he provided scientific 
evidence for a plausible mechanism of transmission of hereditary traits. Developed a little 
more than two decades later by Theodor Boveri and Walter Sutton, working independently, 
the chromosome theory of inheritance, also known as the Sutton-Boveri theory, rightly 
confirmed the chromosomes as the carriers of the genetic material (Harris, 2008; Sutton, 
1903), thus expanding the science of genetics from the organismal level to the sub-cellular 
level. Still, almost another century had to elapse before cancer became widely recognized as 
a disease of the genes. In this section, a brief historical account is presented of the 
discoveries that, directly or indirectly, made a strong contribution to the establishment of 
the genetic basis of cancer. 
1.1 The chromosome theories of cancer formation: From Hansemann and Boveri to 
the Philadelphia chromosome 
In 1890, while studying mitosis in the human epidermis, David von Hansemann analyzed in 
detail 13 different carcinomas and consistently found examples of aberrant mitoses, namely 
multipolar mitoses and asymmetric distributions of chromosomes at anaphase. The 
occurrence of gross mitotic abnormalities in tumor cells had already been reported by 
several pathologists, but it was apparently Hansemann who first argued that aberrant cell 
divisions and the resulting abnormal (or aneuploid) karyotypes were essential determinants 
of malignancy (von Hansemann, 1890, as cited in Bignold et al., 2006). Similarities between 
these mitoses and those occurring during oögenesis, namely the generation of daughter cells 
with a decreased chromatin content (the polar bodies, in the case of oögenesis), seemed to 
support the gametogenic ideas of tumor formation that were current in the nineteenth 
century. These theories linked certain features of tumors, such as their increased capacity for 
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independent growth (section 3), to those of germ cells. However, in the mid-1890s, 
Hansemann had already abandoned the oögenic component of his theories. 
Hansemann’s seminal hypothesis of a link between chromosomes and cancer was largely 
ignored and, still to this day, the chromosomal theory of cancer formation is frequently fully 
credited to Theodor Boveri (Harris, 2008), a zoologist who pursued Hansemann's theory a 
decade later (Harris, 2008). Nonetheless, it has to be acknowledge that Boveri took to a 
higher level this relationship between karyotypic disorders, which he proposed to be mostly 
initiated by multipolar mitosis, and malignancies. Namely, he provided experimental 
evidence that certain chromosome combinations lead to abnormal development and 
proposed mechanisms of malignancy based on novel concepts. 
In the detailed studies that would culminate in his chromosome theory of inheritance, 
Boveri ingeniously devised experimental manipulations to artificially induce multipolar 
mitoses in sea urchin eggs (Harris, 2008). His apparently simple cytological procedures 
represented a major breakthrough: via aberrant chromosome segregations, cells with 
different chromosome complements were produced whose developmental prospects could 
be followed. As a result, pertinent links could be established between individual 
chromosomes and development. Boveri observed that, of the very few blastomeres that did 
not perish, most failed to follow their normal developmental pathways. From these different 
outcomes, he concluded that individual chromosomes were qualitatively dissimilar and that 
normal embryos could only develop when the right combination of chromosomes was 
present. Embryos perished possibly due to the loss of chromosomes involved in cellular 
housekeeping functions. Abnormal development resulted from loss of chromosomes 
involved in cellular functions that, although important, were not essential for the cells' 
viability. Particularly important in the context of tumorigenesis was the finding that, in the 
abnormal embryos that formed, blastula cells soon lost their epithelial contiguity, giving rise 
to irregular formations whose microscopic appearance was “strikingly similar to that of a 
medullary carcinoma”. From this and from the previous recognition that malignant cells 
exhibit abnormal chromosome constitutions, Boveri surmised that “malignant tumors might 
be the consequence of a certain abnormal chromosome constitution, which in some 
circumstances can be generated by multipolar mitoses" (Harris, 2008).  
Later, Boveri expanded his central hypothesis to include other concepts, some of which are, 
nowadays, basic tenets of cancer (Harris, 2008). After decades of intense research, it can now 
be appreciated that his ideas of "inhibitory chromosomes" and "activating chromosomes" 
anticipated the concepts of tumor suppressor genes and proto-oncogenes, respectively 
(section 1.2). He also foretold the existence of cell-cycle checkpoints (section 3), predicted the 
clonal origin of tumors and, implicitly, suggested that genomic instability drives the 
accumulation of chromosome aberrations and mutations in cancer. That many of Boveri's 
hypotheses were later proved correct is the more remarkable, considering that he never 
actually performed experiments with tumor tissue. Quite ironically, this same fact, together 
with his lack of medical training, may partly account for the great deal of skepticism with 
which the medical community met his views on the origin of malignant tumors.  
Experimental proof of some of Boveri’s predictions required the development of adequate 
cytogenetic techniques for counting and characterizing individual mammalian 
chromosomes. For instance, before the establishment of the correct chromosome number 
(i.e., 46), by Tjio and Levan, in 1956 (Tjio & Levan, 1956), the observation of 48 chromosomes 
in human tumors was accepted as normal, as this number was thought to represent the 
normal diploid number (Painter, 1921). 
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To a certain extent, the establishment of cancer as a genetic disease went hand in hand with 
the development of the emerging discipline of genetics. One crucial issue was the molecular 
nature of Mendel's factors or characters, these packets of hereditary information that passed 
discretely from one generation to another and that were responsible for the different 
characteristics of an organism. By the end of the 1880s, Hugo de Vries had developed the 
concept of pangenes, "special particles for every hereditary character" that composed the 
chromosomes (de Vries, 1910).In 1914, Boveri suggested, with remarkable foresight that if 
Mendel’s hereditary units were located in the chromosomes, each chromosome had to 
contain a large number of units, probably arranged in a precise linear order. In his 
influential book "The Cell in Development and Inheritance", published in 1925, Edmund B. 
Wilson still referred to the gene, the term by which Mendel's factors became, by then, 
known, as "an hypothetical elementary entity that is essential to, or determines the 
development of a particular character” (Benson, 2001). In this context, the independent 
discoveries, by Hermann Muller (Muller, 1927) and Lewis Stadler (Stadler, 1928a,1928b), in 
1926–1927, that X-rays could induce mutations (in Drosophila and in barley and maize, 
respectively) were truly far-reaching, as they clearly proved genes to be susceptible to 
damage, transforming Mendel's abstractions into real biological entities. 
In 1960, while studying chronic myelogenous (or myeloid) leukemia, Peter Nowell and 
David Hungerford made a tremendous discovery: tumor cells of this type of leukemia (but 
not of acute myelogenous leukemia) contained a “minute chromosome” that replaced one of 
the four smallest autosomes, a modification that was not present in normal cells of the same 
patients. They proposed the existence of a causal relationship between this chromosome 
modification and the development of this type of leukemia (Nowell & Hungerford, 1960). 
Moreover, the presence of this minute chromosome in all malignant cells of these patients 
lent strong support to Boveri's proposal that tumors originate from a single cell (the 
monoclonal origin of cancer). 
Following the tradition to name each new chromosome after the city in which it was 
discovered, the minute chromosome was named the Philadelphia chromosome. Its true 
nature could finally be unraveled with the development of cytogenetic techniques of 
banding, particularly Giemsa banding (Nowell, 2007). In 1973, Janet Rowley demonstrated 
that it results from a translocation between the long arms of chromosomes 22 and 9 (Rowley, 
1973). Rowley reported other types of translocations in hematopoietic cancers, including a 
translocation between chromosomes 8 and 21 in acute myeloblastic leukemia cells (Rowley 
& Potter, 1976). Later, the genes involved in the Philadelphia translocation chromosome 
were identified: the v-abl Abelson murine leukemia viral oncogene homolog (ABL), on 
chromosome 9, and the breakpoint cluster region gene (BCR), on chromosome 22. Their 
juxtaposition creates a fusion gene which encodes an abnormal tyrosine kinase (Groffen et 
al., 1984; Lugo et al., 1990). 
1.2 From retroviruses to oncogenes and proto-oncogenes 
The hypothesis that cancer could be caused by viruses was put forward in the beginning of 
the twentieth century. Although it is now apparent that the number of cancer types directly 
induced by viruses is rather small, several decades of intense work on the molecular 
mechanisms of viral oncogenesis have, nonetheless, produced significant discoveries in 
cancer research. A special mentioned must be made to Peyton Rous. His discovery, in 1910, 
of an avian sarcoma that could be successfully transplanted to another host of the same 
breed (Rous, 1910) was followed, a year later, by his discoveries that cell-free filtrates of this 
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tumor could cause cancer and that the cancer-causing agent was a "filterable agent", as 
viruses were then called (Rous, 1911). This virus was later named Rous sarcoma virus (RSV), 
after its discoverer. Now regarded as ground breaking, these discoveries were not fully 
appreciated for several decades. Nonetheless, RSV was distributed to many laboratories and 
the slow accumulation of knowledge on this and other viruses that took place in the decades 
that followed eventually led to the discovery of the first oncogene, v-SRC, as well as to that 
of its cellular precursor, c-SRC. In the late 1960s, Robert Huebner and George Todaro 
proposed the "oncogene" hypothesis of cancer, according to which both spontaneous cancers 
and those induced by chemical and physical agents resulted from de-repression of a 
transforming gene of covert C-type RNA viruses (Huebner & Todaro, 1969). Their 
suggestion was based on the observation that particles of this unique class of retroviruses, of 
which RSV is the most famous example, were found to be present in almost all vertebrate 
species and could be vertically (i.e., genetically) transmitted from cell to progeny cell and 
from animal to progeny animal. As the induced expression of this gene transformed normal 
cells into tumor cells, they named it an oncogene. In 1970, G. Steve Martin identified a RSV 
mutant that was temperature sensitive for transformation, but replicated at the non-
permissive temperature. The discovery of this transformation-specific defect was an 
important step in the physical identification of the viral gene responsible for the 
transforming action of RSV (Martin, 1970), as it led to identification, by Peter Duesberg and 
Peter Vogt, of RNA sequences in the genome of RSV that were missing in the replication 
competent, but transformation-defective viral variants (Duesberg & Vogt, 1970). Finally, in 
1976, Dominique Stehelin, Michael Bishop and Harold Varmus identified the first retroviral 
oncogene: SRC (Stehelin et al., 1976a). Based on the intriguing fact that SRC was dispensable 
for virus replication, Bishop and Varmus speculated that it might be a cellular gene that was 
captured by the transforming virus. In subsequent studies using cDNA hybridization 
techniques, Bishop, Varmus and colleagues demonstrated the existence of v-SRC related 
sequences in the genome of birds (Stehelin et al., 1976b). To emphasize the lack a direct 
transforming action, unless mutated or overexpressed, this new type of gene, c-SRC, 
precursor of viral oncogenes, was designated a proto-oncogene (Iba et al., 1984; Parker et al., 
1984). The discovery of c-SRC triggered a frenzy of research into the roles of oncogenes, 
allowing for a better understanding of the signal-transduction pathways that control several 
biological processes. Of note was the finding that SRC is active in many human epithelial 
cancers (Bolen et al., 1987; Jacobs & Rubsamen, 1983; Yeatman, 2004). 
1.3 From hereditary cancers to tumor suppressor genes 
The idea that multiple mutations on DNA, both in somatic and germ-line cells, and the 
formation of cancer are closely related can be traced back to the beginning of the twentieth 
century (Bignold et al., 2006). In 1953, Carl Nordling analyzed the incidence of cancer in 
some countries and related it with the age and gender of the population, concluding that 
about six mutations (or hits) are concordant with the age when cancer usually emerges. He 
explained the high incidence of tumors in children by a higher rate of cell division during 
fetal development and, concomitantly, an enhanced accumulation of mutations (Nordling, 
1953). However, it was just in 1971, with Alfred Knudson, that the multiple-hit theory 
gained firm ground. Knudson made a statistical analysis of cases of retinoblastoma, a tumor 
of the retina, which occurs both sporadically and as an inherited disease. He analyzed the 
occurrence of both unilateral and bilateral tumors (i.e., occurring in a single or in both eyes, 
respectively) and established that retinoblastoma was caused by two mutations. In bilateral 
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cases (familial cases), a mutation is inherited and the second mutation occurs after.  
In unilateral patients with sporadic cancers, both mutations are somatic. His hypothesis 
explained why a child born with the first hit in all cells was more likely to develop cancer in 
both eyes at an early stage and why a child who needed to have two mutations on somatic 
cells would probably just develop cancer in one eye (Knudson, 1971). Later,  
the retinoblastoma gene (Rb gene) was localized to chromosome 13 and unilateral and 
bilateral cancers were found to have the same second mutation in the Rb gene, indicating 
that cancer development occured after inactivation of the second allele of the gene (loss  
of heterozygosity) (Cavenee et al., 1983). The first tumor suppressor gene, Rb, was 
identified (Lee et al., 1987). In 1988, Harbour found abnormalities in the Rb gene in small 
cell lung cancer (Harbour et al., 1988). In the next years, multiple oncogenes (NEU, c-MYC, 
c-MYB, RAS) and tumor suppressor genes (Tp53, Rb) were found to be modified in 
different types of cancer. 
2 DNA lesions: Types, origins and consequences 
The genome is inherently unstable, undergoing spontaneous chemical reactions in the 
aqueous nuclear milieu, such as hydrolysis of nucleotide bases and non-enzymatic 
methylations. Genome integrity is also constantly compromised by occasional mismatches 
introduced by DNA polymerases during replication and by DNA strand breaks generated 
as a consequence of abortive activities of topoisomerases I and II. Finally, the genomes of all 
organisms are continuously exposed to a myriad of endogenous and exogenous agents that 
also produce DNA lesions (Jackson & Bartek, 2009). Altogether, these factors are responsible 
for the emergence of tens of thousands of DNA lesions per cell per day that corrupt our 
genetic information. These DNA lesions are varied and are frequently related to the nature 
of the genotoxic agent that produced them (Jackson & Bartek, 2009). They include adducts, 
oxidized bases, abasic sites, DNA crosslinks, single-strand breaks (SSBs) and, less 
frequently, double-strand breaks (DSBs). Although rather infrequent, these latter lesions are 
extremely toxic and difficult to repair. This section will briefly describe types, origins and 
consequences of DNA lesions that may be involved in tumorigenesis. 
There are multiple examples of spontaneous hydrolytic reactions occurring at the level of the 
DNA molecule, such as the hydrolytic deamination of the DNA base cytosine, leading to the 
formation of the aberrant base uracil. This type of reaction has a high rate of occurrence (~100-
500 times per human cell per day), particularly in regions of single-stranded DNA, such as 
replication forks, where protection of cytosines by the complementary strand is missing. Its 
incidence also increases with unmethylated cytosine. If this lesion stays unrepaired, point 
mutations C:G to T:A will occur upon DNA replication (Barnes & Lindahl, 2004; Parker & 
Stivers, 2011; Shen et al., 1994). Misincorporated uracils can be removed at a high rate by DNA 
glycosylases of the base excision repair (BER) pathway (section 4), generating gaps in the DNA 
strands. This type of gap that does not contain any base, i.e., neither a pyrimidine nor a purine 
are known as AP (apurinic/apyrimidinic) or abasic sites. The main problem is that adenine 
and guanine can also be removed from the DNA strands at a similar high rate. As the resulting 
AP sites are identical in all cases, the repair machinery will randomly incorporate a new base. 
Fortunately, this probably does not occur to a significant extent in vivo (Barnes & Lindahl, 
2004). Non-enzymatic hydrolysis of DNA bases (i.e., hydrolytic depurination) is another 
mechanism of production of abasic sites. Hydrolytic deamination is also responsible for the 
conversion of guanine, adenine and 5-methylcytosine to xanthine, hypoxanthine and thymine, 
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respectively, a process that can also be induced by X-rays, oxygen radicals or alkylating agents 
(Barnes & Lindahl, 2004; Hoeijmakers, 2001). Hypoxanthine forms a more stable base pair with 
cytosine than with thymine, leading to A:T to G:C transversions. Xanthine also pairs 
preferentially with cytosine, but with less coding specificity. So, the formation of hypoxanthine 
may be more dangerous from the point of view of formation of premutagenic lesions (Lindahl, 
1993). The formation of thymine gives rise to G:T mispairs, frequently observed at CpG islands 
(Shen et al., 1994). 
Amongst endogenous genotoxic agents are certain by-products of physiological processes. 
Some of them, particularly reactive oxygen species (ROS) (Cooke et al., 2003) produced 
during aerobic cellular respiration, represent a considerable threat to genome integrity. One 
damaging effect of these reactive species is the loss of DNA bases. ROS, as well as nitrogen 
reactive species, are also formed at sites of inflammation and infection by neutrophils and 
macrophages (Kawanishi et al., 2006) and some of these reactive species can also be 
generated by environmental agents through redox-cycling processes, by Fenton reactions 
mediated by heavy metals (e.g., iron) and by ionizing radiation. The main modification that 
ROS introduce into the DNA backbone is the oxidation of guanine, generating 7,8-dihydro-
8-oxoguanine (8-oxo-guanine). Contrary to its normal counterpart, the oxidized base 
interacts with cytosine and adenine nucleotides with almost the same affinity, eventually 
causing the transversion mutation from G:C to T:A (Bruner et al., 2000). This same point 
mutation can result from the action of a variety of mutagens that also produce ROS, such as 
ultraviolet (UV) and ionizing radiation (see below). Not surprisingly, it is the second most 
frequently found somatic mutation in human cancers and is commonly found in the 
mutational spectrum of Tp53 gene (Bruner et al., 2000). 
The modification of bases is by no means restricted to the formation of 8-oxo-guanine. For 
instance, the highly mutagenic O6-methylguanine can be formed by external alkylating 
agents (e.g., N-methylnitrosourea) through transfer of a methyl group to the oxygen atom of 
a guanine. The modified base can also pair with thymine, and not only with cytosine 
(Barnes & Lindahl, 2004). 
UV light (Kapetanaki et al., 2006), ionizing radiation and various chemicals (Kondo, 1977; 
Shrivastav et al., 2010) are examples of exogenous genotoxic agents. Some of them, such as 
UV light, ionizing radiation and tobacco-derived chemicals, have been firmly established, by 
epidemiologic, animal and in vitro studies, as carcinogens. Exposure of the skin to UV 
radiation (both UV-A and –B; see below) is linked to skin cancer, both melanoma and non-
melanoma. Cancers of the lung, oral cavity and adjacent tissues, amongst others, are known 
to be induced by tobacco-derived chemicals, probably the most prevalent environmental 
cancer-causing chemicals. 
Under strong sunlight, UV radiation is a potent promoter of DNA lesions (Jackson & Bartek, 
2009). According to its wavelength, this radiation can be classified into UV-A (320–400 nm), 
-B (280–320 nm) and –C (200–280 nm). Fortunately, the ozone layer in the upper atmosphere 
completely absorbs the most energetic component, i.e., UV-C, as well as a significant portion 
of the UV-B component, with only about 1-10% of this latter component actually reaching 
the earth. However, the major part (90–99%) of UV-A radiation crosses the atmosphere, 
reaching the earth surface (Bachelor & Bowden, 2004). Although this radiation is not 
energetic enough to produce direct DNA damage, it, nonetheless, produces indirect 
damage, mainly through the induction of free radicals and singlet oxygen (Wang et al., 
2001). On the contrary, the more energetic UV-B radiation can interact directly with DNA, 
thus presenting an enhanced mutagenic and carcinogenic action. 
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The main DNA lesions generated by UV-B radiation are pyrimidine dimers, which are both 
cytotoxic and mutagenic (Lindahl & Wood, 1999). Upon sunlight exposure, each cell of 
exposed skin may suffer 50-100 such lesions per second. This type of radiation can be 
absorbed by the 5-6 double bonds of DNA pyrimidines, allowing them to open. When two 
pyrimidines are adjacent in a DNA molecule, covalent bonds can form between them. The 
most frequent product of this reaction is a four-membered ring [a cyclobutane-type 
pyrimidine dimer (CPD)], resulting from the formation of two bonds between the 
neighboring bases. Less frequently, only one bond forms between the two pyrimidine 
molecules, giving rise to a 6,4-photoproduct (Goodsell, 2001). The formation of dimers 
induces local distortions in the DNA helix that weaken base pairing. As a result, these 
dimers can be misread during replication, introducing mutations. The signature mutations 
caused by UV light involve C to T mutations, caused when cytosines are mispaired with 
adenine bases during replication. The replacement of one cytosine by one thymine accounts 
for 70% of the UV-induced mutations and 10% of mutations involve the replacement of both 
cytosines by two thymines (Brash, 1997; Sage et al., 1996). These signature mutations are 
frequently detected in the Tp53 tumor suppressor gene of most human non-melanoma skin 
cancers (Bruner et al., 2000), compromising its watchdog function (section 3), which strongly 
points for an important role in carcinogenesis. 
Interstrand crosslinks (ICLs), which involve the formation of a covalent bond between 
nucleotides of both strands, are also highly dangerous lesions. Given that these crosslinks 
involve both strands of DNA, they inhibit strand separation during replication and, 
consequently, prevent transcription and translation. A variety of bi-functional alkylating 
agents, including platinum compounds, mitomycin C, nitrogen mustards and psoralen, can 
induce this type of lesion. The interstrand crosslink structure formed depends on which 
compound interacts with DNA and, consequently, the nature of its repair is diverse (Hlavin 
et al., 2010). 
SSBs on the DNA backbone can be produced by both endogenous and exogenous agents, 
namely ROS and alkylating compounds, respectively. The formation of this type of lesion is 
intrinsically linked to the presence of AP sites on the DNA molecule and with the activity of 
the BER system (Hoeijmakers, 2001). The major concern about SSBs is that they can be 
precursors for a foremost dangerous lesion, i.e., DSBs. Indeed, when two SSBs arise in close 
proximity, or when the DNA-replication apparatus encounters a SSB, DSBs are formed. 
DSBs can also be induced by some anti-tumoral agents that induce ROS generation. These 
lesions have a particularly high incidence in telomeric regions due to imperfect metabolism 
of chromosome ends (Khanna & Jackson, 2001). 
The genome can also be modified on a large-scale basis through modifications in the 
structure and/or number of copies of chromosomes. Changes in chromosome structure, 
termed rearrangements, can occur by multiple processes, particularly by deletion or 
duplication of a chromosome portion, by inversion (modification of DNA orientation) or by 
translocation. The main cause of these chromosomal modifications is the breakage of DNA 
in two different locations, followed by a rejoining of the broken ends, which leads to a 
different chromosome organization (Nambiar & Raghavan, 2011). In the particular case of 
translocations, which exhibit a high prevalence in different types of cancer (section 1 and 
below), the lesion is formed when a segment of a given chromosome is moved to a different 
chromosome. The simplest type of translocation is the reciprocal translocation, usually 
involving change of genetic material between non-homologous chromosomes. As a 
consequence, translocations can cause recombination of normally separated genes (fusion 
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genes) or juxtaposition of the entire coding region next to an active promoter of other gene 
(Griffiths et al., 2004). 
Chromosome translocations are commonly observed on hematological cancers. About 90% 
of lymphomas and 50% of leukemias contain translocations (Nambiar & Raghavan, 2011). A 
translocation of genetic material between chromosomes 8 and 14 (t(8:14)(q24:q32)) is found 
on 80% of all cases of Burkitt lymphoma, resulting in the fusion of c-MYC (section 3), from 
chromosome 8, with a gene coding for a heavy-chain of a immunoglobulin (Hecht & Aster, 
2000; Taub et al., 1982). This translocation results on c-MYC overexpression, because it is 
placed under the control of 3’ regulatory elements of the immunoglobulin (Hecht & Aster, 
2000). The Philadelphia chromosome (section 1), which has a high incidence in chronic 
myelogenous leukemia, results from a translocation between the chromosomes 9 and 22, 
forming an aberrant BCR-ABL gene on chromosome 22. The protein expressed by this fusion 
gene has a constitutively tyrosine phosphokinase activity, which is essential for the 
oncogenic potential of BRC-ABL. This translocation is also found in acute lymphoblastic 
leukemia, but with a lower incidence (Kurzrock et al., 2003). These cases exemplify the 
activation of a gene through its insertion next to a promoter and the overexpression of a 
fusion gene, respectively.   
Translocations have also been found in solid tumors. For example, gene fusion was 
observed in a large number of prostate carcinomas, with TMPRSS2–ERG as the most 
common form. ERG overexpression is associated with in vitro invasiveness by activation of 
metalloproteinase pathways (Kumar-Sinha et al., 2008). For a list of translocations associated 
with non-lymphoid malignancies, the reader is referred to (Nambiar et al., 2008). 
Despite their frequent occurrence in tumors, the exact mechanism of translocation formation 
is not fully understood. However, it is well known that formation of DSBs is essential 
(Khanna & Jackson, 2001). On hematopoietic tumors, chromosomal translocations usually 
involve the immunoglobulin locus on chromosome 14 and some data suggest that V(D)J 
recombination, a site-specific reaction necessary for the assembly of antigen receptor genes 
in developing B and T lymphocytes (Nussenzweig & Nussenzweig, 2010), may have an 
important role in this process (Nambiar & Raghavan, 2011). 
3. The hallmarks of cancer and their genetic underpinnings 
Advances in the last century allowed us to comprehend at the cellular and molecular levels 
tissue architecture and function in metazoans. During embryonic development, tailoring of 
new tissues is achieved through cell-cell competition: when two cell subpopulations with 
the same ancestry, but different growth potentials arise, faster-growing cells induce 
apoptosis in slower-growing ones and later engulf them, achieving a higher relative 
contribution to the adult tissue (Johnston, 2009). In adults, almost all organs possess niches 
harboring lineage-specific adult stem cells, which can be stimulated upon injury to produce 
progenitor (or transit amplifying) cells. These will then divide a certain number of times to 
regenerate the tissue, until they eventually become terminally differentiated (He et al., 2009). 
Cell growth and division occur in a periodical manner throughout a cell’s proliferative life. 
Experiments in plants carried out in the early 1950s established that each cell had DNA 
“units” characteristic of its particular strain. The amount of this DNA duplicated during 
growth and was halved during gamete production (Swift, 1950). Later studies using DNA 
labeled with radioactive phosphorus (32P) permitted a more accurate analysis of the DNA 
content throughout the cell cycle (Howard & Pelc, 1953), which suggested a partition in 
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phases that still holds today (Sisken & Morasca, 1965). Cell cycle can be broadly divided in 
interphase and mitotic (M) phase. Interphase is a phase of growth during which 
metabolically active cells prepare themselves for cell division. It can be further divided in 
Gap 1 (G1), when cells receive external stimuli to grow, Synthesis (S), when DNA 
duplication occurs, and Gap2 (G2), which serves for cells to continue augmenting their size 
and ensuring that the mitotic machinery is ready. M phase can be further divided into 
mitosis, i.e., the division of the nucleus (and its chromosomes), and cytokinesis, i.e., division 
of the cytoplasm, giving rise to two daughter cells, genetically identical to each other and to 
the mother cell (Morgan, 2007).    
Apoptosis is the programmed cell suicide that occurs following specific signals, which may 
be either intracellular stresses or external signals (intrinsic and extrinsic program of 
apoptosis, respectively). The main purpose of this cellular program is the protection of 
organisms from eventual deleterious effects of individual defective cells (Kerr et al., 1972). It 
is always an unbalance between pro- and anti-apoptotic proteins (Adams & Cory, 2007) that 
triggers a cascade of cellular events, ultimately leading to activation of dormant cysteine 
proteases, the caspases, whose effector members provoke controlled cell disintegration 
(Danial & Korsmeyer, 2004).  
Under normal conditions, cell cycle progression is tightly regulated (Rajewsky & Muller, 
2002). When genomic integrity is compromised beyond a certain level, apoptosis ensues in 
order to guard the viability and function of the organism as a whole (Kerr et al., 1972; 
Levine, 1997). In stark contrast, the high genomic instability existent in tumor cells, which 
may result, for instance, from overall DNA hypo-methylation (Eden et al., 2003) or 
deficiency in mismatch repair (MMR; discussed in the next section) (Parsons et al., 1993), 
gives rise to a set of mutations in growth-related genes that bestows cancer cells with 
enhanced growth and down-regulated apoptosis. These properties work in combination as a 
potent driving force of the aggressive capacity of neoplasias to rapidly evolve and 
proliferate (Campbell et al., 2010). 
Mutations with carcinogenic potential are mainly restricted to two classes of genes: proto-
oncogenes and tumor suppressor genes. Proto-oncogene products are involved in 
development and tissue maintenance, usually having a stimulatory effect on cell growth; 
their mutated versions are called oncogenes and are, by definition, capable of inducing 
cancer through constitutive activation of proliferation (Adamson, 1987). On the other hand, 
tumor (or growth) suppressor gene products restrain cell growth and division and may 
even elicit apoptosis. The Tp53 gene is a well-known example (Levine, 1997).     
As mentioned before (section 1), the term cancer does not designate a single pathology, but 
rather over 100 distinct neoplastic diseases (or types of cancer) best known by an 
uncontrolled multiplication of abnormal cells. The observation, in pathological analyses, of 
particular lesions that seemed to represent intermediate, or premalignant, states between 
normalcy and invasive cancers strongly suggested that human tumorigenesis is a multistep 
process. Paradoxically, carcinogenesis and normal aging share more traits than previously 
suspected, including increasingly heterogeneous gene expression patterns (Bahar et al., 2006; 
Campbell et al., 2010) and modifications in DNA repair systems (Finkel et al., 2007). The fact 
that the genomes of tumor cells invariably exhibit multiple alterations, ranging from the 
gross changes in chromosome complement, identified more than a century ago (section 1), 
to single base substitutions (i.e., point mutations; e.g., Kinzler & Vogelstein, 1996), led to the 
concept of cancer as a genetic disease. Thus, according to the dominant paradigm, 
carcinogenesis involves the successive acquisition of genetic alterations that confer certain 
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growth advantages (Fearon & Vogelstein, 1990). These alterations, when co-adjuvanted by 
chronic exposure to a growth promoter (Berenblum & Haran, 1955), act as a positive 
feedback loop, allowing further genetic alterations to accumulate. As a result, normal cell 
proliferation and homeostasis are progressively subverted, driving the stepwise 
transformation of normal human cells into increasingly malignant tumor masses. Taken 
together, these and other observations depict neoplastic transformation as a micro-
evolutionary process: its inception depends on the ab initio transformation of a single cell 
and on the natural selection pressures that this transformed cell must overcome in order to 
thrive and proliferate in a specific hostile microenvironment, giving rise, through successive 
rounds of clonal selection, to a tumor mass, from which a subset of cells, possessing 
clonogenic potential, will invade surrounding and, ultimately, distant tissues (Aslakson & 
Miller, 1992). 
In 2000, Hanahan and Weinberg, construing the seminal discoveries on the molecular basis 
of cancer achieved during the twentieth century, hypothesized that, in spite of their 
remarkable diversity, all neoplastic diseases might be rationalized in terms of a small 
number of underlying principles. At the time, they identified six well-defined traits 
(hallmarks) acquired by most, if not all, animal cells during their progressive transformation 
into fully malignant derivatives: self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis (Hanahan & 
Weinberg, 2000). Very recently, and based on the intense research performed in this field 
during the last decade, the same authors updated this conceptual framework of cancer 
biology and included genomic instability as an instrumental, enhancing characteristic of 
tumorigenesis (Hanahan & Weinberg, 2011). Other emerging topics are tumor-associated 
cells and bioenergetics. 
This section will briefly address the regulatory circuits that govern normal cell proliferation 
and homeostasis and then describe some of the genetic reprogramming that may underlie the 
hallmarks of cancer. It must be stressed that, although this chapter focuses on genetic 
alterations, it is now well established that epigenetic changes can be adjuvants or even 
surrogates of genetic mutations: for instance, specific DNA hypermethylation leads to 
silencing of tumor suppressor genes (Herman & Baylin, 2003) and hypo-methylation not only 
allows up-regulated transcription of oncogenes (Nishigaki et al., 2005), but also, when 
generalized, genomic instability (Eden et al., 2003). This additional layer of complexity sheds 
light on the conspicuous heterogeneity of cancer cell populations (Feinberg et al., 2006) and 
accommodates the groundbreaking report of the generation of a whole mouse by transference 
of a melanoma cell nucleus into a normal oocyte. Thus, at least for some cancers, alterations 
that lead to aberrant development and malignization may be essentially perennial, rather than 
engraved in the genome (Hochedlinger et al., 2004). Probably even more impressive is the fact 
that normal cells belonging to tumor stroma may behave as co-conspirators. For instance, 
cancer-associated fibroblasts may actively contribute to tumor initiation (Hayward et al., 2001) 
and progression (Olumi et al., 1999) and senescent fibroblasts were shown to foster 
tumorigenic potential of neoplastic cells (Krtolica et al., 2001). 
3.1 The regulatory circuits that govern normal cell proliferation and homeostasis 
Eukaryotic cells are dependent on paracrine signaling to progress through the G1 phase of 
the cell cycle: growth factors produced by neighboring cells, such as endothelial growth 
factor (EGF) and platelet-derived growth factor (PDGF), are sensed by receptor tyrosine 
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kinases (RTKs) (Robinson et al., 2000). These extracellular cues are internalized by RTKs 
through the activation of the highly conserved mitogen-activated protein kinase (MAPK) 
pathway, more specifically the RAS/RAF/MEK/ERK pathway (Mcubrey et al., 2007). This 
protein kinase cascade is responsible for conveying and amplifying extracellular signals of 
growth factors to transcription factors that activate expression of genes essential for cell 
cycle progression (Aktas et al., 1997), such as c-FOS and c-MYC (Armelin et al., 1984; Kruijer 
et al., 1984). When the environment is hostile, either due to deprivation of growth factors 
(Zetterberg & Larsson, 1985) or nutrients (Tobey & Ley, 1970), or upon contact inhibition 
(Nilausen & Green, 1965), cells stop dividing in a reversible manner. When this mechanism 
of adaptation was initially observed, termed negative pleiotypic response at that time 
(Hershko et al., 1971), it was controversial whether cells were fixed somewhere in G1 or 
whether cell cycle was effectively abandoned. Later findings have shown that several cell 
growth inhibitory conditions lead to cell cycle exit to a quiescent viable state, or G0 phase, at 
a particular point of G1 (Pardee, 1974). This point, termed the restriction (R) point, is now 
known to be the checkpoint for entrance in S phase (Harbour & Dean, 2000). Tp53, widely 
known as caretaker of genome integrity (Levine, 1997), was attributed a central role in 
triggering and maintaining this quiescent state in human cells (Itahana et al., 2002). Despite 
this apparent unity, it was found that different growth inhibitory conditions (e.g., serum 
withdrawal and high cell density) may trigger quiescence through distinct genetic 
mechanisms (Gos et al., 2005). 
What is, then, the molecular basis governing commitment to cell division? Curiously, a 
single locus in the short arm of chromosome (9p21), CDKN2a, codes two paramount 
proteins in R point regulation, p16INK4a and p14ARF (Quelle et al., 1997). p16INK4a inhibits 
cyclin-dependent kinases (CDKs) 4 and 6, responsible for the phosphorylation of 
retinoblastoma protein, Rb, the guardian of the R point. While in the hypo-phosphorylated 
state, Rb halts entry into S phase by imprisoning proteins of the elongation factor 2 (E2F) 
family necessary for the transcription of genes involved in DNA synthesis. In the presence 
of extracellular growth stimuli, p16INK4a inhibition takes place, allowing entry into S phase 
(Harbour & Dean, 2000); it is noteworthy, however, that excessive mitogenic signaling can 
actually activate p16INK4a (Lin et al., 1998) and induce senescence. On the other hand, ARF 
represses HDM2, a negative regulator of Tp53, in turn responsible for promoting cell cycle 
arrest via enhanced transcription of GADD45, a PCNA-binding protein (Levine, 1997). This 
frugality of nature in allocating in the same locus two cell cycle inhibitors acting upstream 
the most preponderant cell division regulators, Rb and Tp53, is very rare in mammalian 
genomes. Interestingly, insertion of cancer-associated p16INK4a/p14ARF locus mutations in 
mice, whilst compromising G1 arrest through p16INK4a, did not affect ARF function (Quelle 
et al., 1997). These findings are biologically sound: though the action of Rb as a downstream 
element of Tp53-driven cell cycle arrest (Hahn & Weinberg, 2002) might suggest the 
existence of a single pathway involving these two proteins, it is long known that, whereas 
p16INK4a induces G1 arrest, p14ARF can block cell cycle both at G1 and G2 phases (Quelle et 
al., 1995). In fact, the number of independent functions ascribed to these tumor suppressors 
has been growing remarkably: Tp53 functions as a cell death arbiter, triggering apoptosis in 
response to genotoxic (Levine, 1997), acidic (Williams et al., 1999) and hypoxic (Hammond & 
Giaccia, 2005) stresses, acting also as a bioenergetic switch (Ma et al., 2007), while Rb has 
been shown to carry out its tumor suppressor activity also via cell cycle-independent 
transcriptional promotion of differentiation (Sellers et al., 1998), being neuronal migration a 
recently described example (Mclellan et al., 2007). Finally, it is important to note that much 
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remains to be known about the integration of Tp53 and Rb pathways at the organismal 
level, as mice genetically engineered to harbor individual cells lacking either Tp53 
(Ghebranious & Donehower, 1998) or Rb (Lipinski & Jacks, 1999) displayed no neoplasias, 
exhibiting only a greater tendency to develop malignancies late in life. 
Apart from growth factors, normal cells need also to be anchored on a substratum in order 
to proceed in cell cycle (Schulze et al., 1996). This is due to the dependence of Cyclin A gene 
expression, a crucial event for DNA replication (Girard et al., 1991), on cell anchorage. 
Indeed, forced expression of Cyclin D1 was sufficient to ablate blockade of Cyclin A 
expression and, concomitantly, cell cycle progression (Schulze et al., 1996). This cell cycle 
regulator associates with CDKs 4 and 6 (Sherr & Roberts, 1999), eliciting Rb phosphorylation 
and, consequently, entrance into S phase, as described above (Harbour & Dean, 2000). 
Actually, the sustenance of a feature classically associated with tumorigenic and metastatic 
potential, anchorage-independent growth (Shin et al., 1975), is achieved through constitutive 
activation of Cyclin D1 proto-oncogene via mutations, translocations or amplification 
(Moreno-Bueno et al., 2003). Furthermore, in that state of anchorage-independent growth, 
the expression profiles of surface adhesion molecules, essential for the establishment of 
anchorage-dependent growth, are tightly regulated to favor growth and metastasis: AKT, 
activated through direct phosphorylation by up-regulated integrin-linked kinase (ILK), 
increases integrin expression, leading to malignization and invasiveness (Mizejewski, 1999; 
Persad et al., 2001; Persad & Dedhar, 2003), whereas loss of vinculin fosters anchorage-
independent growth (Rodriguez Fernandez et al., 1993; Rodriguez Fernandez et al., 1992) 
and downregulates the tumor suppressor phosphatese and tensin homolog (PTEN) 
(Subauste et al., 2005).  
3.2 Subversion of growth signaling pathways 
One of the characteristics of cancer cells that have long intrigued scientists is their autonomy 
relatively to the surrounding tissues. Cancer cells have developed several strategies to 
outwit normal proliferation homeostasis within an organism, namely self-sufficiency in 
growth signals and insensitivity to growth-inhibitory signals. Although much remains to be 
known concerning the precise cellular and molecular mechanisms underlying these 
capabilities, likely to be cancer-type specific, it is now clear that several cancer cell types 
engage in autocrine growth signaling: by synthesizing and extruding to the extracellular 
medium growth factors that are recognized by their own surface receptors, these cells 
trigger their own proliferation (Grivennikov & Karin, 2008; Pandey et al., 2008). A classical 
example is transforming growth factor alpha (TGF-α), initially discovered in retrovirus-
transformed cells (de Larco & Todaro, 1978), which competes with EGF for its receptor, 
EGFR, due to structural similarity (Marquardt et al., 1984). TGF-α autocrine overactivity is a 
common feature of cancers, being TGF-α amplification one of the underlying mechanisms 
(Yung et al., 1990), revealed essential for growth initiation of cancer cells (Jiang et al., 1998). 
Additionally, some tumors display mutated versions of EGFR that chronically impinge on 
signaling pathways, independently of any stimulation by their respective ligands (Boerner et 
al., 2003). 
But how do these cells sustain the resultant constitutive growth? It is now evident that, 
during carcinogenesis, cells undergo a profound reset of their signaling pathways 
downstream of this unchecked stimulatory input, usually also through mutations in proto-
oncogenes. Paradigmatic examples are RAS and RAF (Davies & Samuels, 2010), as 
mutations in these genes lead to production of abnormal proteins that drive constitutive 
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stimulation of cell growth and proliferation in cancer cells through chronic activation of the 
MAPK cascade (Mcubrey et al., 2007). Furthermore, cancer cells are also reprogrammed to 
be intrinsically resistant to antigrowth signaling. This is achieved either through 
downregulation or deleterious mutations of transforming growth factor (TGF)-ǃ receptors 
(Stover et al., 2007), whose ligand, TGF-ǃ suppresses c-MYC expression (Pietenpol et al., 
1990). c-MYC is a proto-oncogene whose product, c-MYC, orchestrates the expression of a 
myriad of genes involved in cell growth and metabolism, being mutated in ca. 30% of all 
human cancers (Dang et al., 2008). Strikingly, c-MYC transcription factor is a keystone in 
malignant dedifferentiation since it has the unique capacity to activate a core set of genes 
associated with embryonic stem cells in human epithelial primary and tumor cells alone 
(Wong et al., 2008).  
3.3 Getting immortal: Proliferation enhancement and apoptosis short-circuiting  
At the beginning of the last century, it was believed that cultured mammalian cells were 
immortal if the proper culture conditions were provided. This belief was based on claims by 
the Nobel laureate Alexis Carrel that chick fibroblasts had been continuously maintained in 
his laboratory for more than 30 years (Carrel & Ebeling, 1921). However, this remarkable 
achievement could never been reproduced by other researchers, and it was found later that 
it had been merely the result of a regular addition of chick embryonic stem cells to the 
culture by technicians, unbeknownst to him (Witkowski, 1980). In 1961, Leonard Hayflick 
clearly established that cells have a limited replicative span, independently of culture 
conditions or surrounding cells (Hayflick & Moorhead, 1961), after which they completely 
stop dividing, irreversibly entering a state called replicative senescence (RS) (Pardee, 1974). 
With the cells used (human diploid fibroblasts, the number of cell divisions necessary for RS 
to be reached (later called the Hayflick) was approximately 50. The molecular basis of this 
limit has been already established. After each round of replication, chromosomes get 
shorter, due to an ineptitude of the replication complex to fully replicate chromosome ends 
(the end-replication problem (Watson, 1972)). Briefly, during DNA replication, DNA 
polymerase needs an RNA primer to start copying DNA. As it works in the 5’-3’ direction, 
the only perfect template is the 3’-5’ (leading) mother strand. The other (lagging strand) 
loops back on it and can be copied using multiple RNA primers. After the synthesis of DNA 
between RNA primers, which are later degraded, the replication complex ligates those DNA 
fragments, but is incapable of synthesizing in the 3’-5’ direction (Johnson & O'donnell, 2005). 
Hence, to prevent the erosion of genes (and also to avoid the end-joining of chromosomes 
(Blackburn, 2000)), the natural ends of eukaryotic chromosomes are protected by telomeres. 
These are nucleoprotein structures containing repetitive DNA sequences capped by a 
multiprotein complex named shelterin. Thus, telomere shortening following each cell 
division functions as a hardwired program to limit the cellular life span, independently of 
growth stimuli, and may be considered as a biological “replicometer” (Hayflick, 2000). The 
hypothesis that the gradual diminution of telomeres could ultimately lead to replicative 
senescence was first put forward by Olovnikov (Olovnikov, 1973). Evidence strutting this 
theory came later from studies in human fibroblasts showing that telomere length strongly 
correlates with replicative span (Allsopp et al., 1992), possessing a threshold value below 
which replicative senescence is triggered (Steinert et al., 2000). Telomerase, a reverse 
transcriptase capable of synthesizing telomeric DNA using an internal RNA template 
(Blackburn, 2000), is not expressed in human somatic cells (Kim et al., 1994). 
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Recently, a spectacular reversal of the aging process of severely aged transgenic mice 
deficient in telomerase was observed upon reactivation of telomerase and concomitant 
telomere lengthening (Jaskelioff et al., 2010). A less mentioned, but also relevant, telomere 
maintenance mechanism, occurring in both normal (Dunham et al., 2000) and cancer human 
cells (Muntoni & Reddel, 2005), is alternative telomere lengthening (ALT). ALT relies on 
homologous recombination (HR), where telomeric DNA is synthesized using another 
telomere as a template. Interestingly, HR, a cell cycle-dependent DNA repair strategy 
usually employed when sister chromatids are available, i.e. after DNA duplication during S 
phase, is central for cancer aggressiveness and the acquisition of drug resistance (Helleday, 
2010). Still, the relation between telomere length and cellular replicative span is not clear cut, 
as immortalization of human fibroblasts via ectopic expression of telomerase did not 
augment telomeres (Zhu et al., 1999). In primary human bronchial fibroblasts, this procedure 
actually bestowed immortality to cells with net telomere shortening (Wise et al., 2004). This 
is in harmony with other cell regulatory roles recently ascribed to telomerase, namely 
interaction with ǃ-catenin, an important inducer of adult stem cell proliferation (Reya & 
Clevers, 2005), to activate WNT-dependent genes (Park et al., 2009).   
Unlike their normal somatic counterparts, but in common with germline cells, the vast 
majority of cancer cells express high levels of telomerase, which allows them to overcome 
replicative senescence and gain immortality (Kim et al., 1994). Still, this strategy may also be 
interpreted as a hurdle for the generation of chromosomal aberrations, a hallmark of 
carcinogenesis (Hanahan & Weinberg, 2011). In fact, telomeres are, by definition, the 
structures that maintain gene integrity throughout cell divisions and impede chromosome 
end-joining (Blackburn, 2000). In fact, experiments in mice (Chin et al., 1999) and, more 
recently, in humans (Lantuejoul et al., 2010) strongly suggest that the initial phase of 
carcinogenesis is marked by severe telomere shortening and concomitant genomic 
instability. Pre-neoplastic cells capable of enduring this scenario, namely through ablation of 
the Tp53 genome guardian function (Levine, 1997), may then experience a reactivation of 
telomerase, earning carte blanche for unchecked growth, division and accumulation of 
mutations (Hanahan & Weinberg, 2011). 
Rather surprisingly, it was recently discovered that senescence, considered a paramount 
barrier to early tumorigenesis, can actually be driven by oncogene activation, rebating the 
common thinking that cell proliferation would increase indefinitely upon oncogene 
activation. In contrast with replicative senescence, oncogene-induced premature senescence 
cannot be attributed neither to high division rates nor to telomere erosion, as it is absent in 
normal epithelial proliferation, inflammatory responses and in cells expressing telomerase 
(Bartkova et al., 2006). Whereas some oncogenes, such as RAS, induce senescence through 
p16INK4a up-regulation (Serrano et al., 1997), breakthrough studies indicated that others act by 
eliciting DNA repair: in particular, differential labeling with the thymidine analogues IdU 
and CldU has shown that induction of Cyclin E oncogene expression led to premature 
termination of most DNA replication forks, and that the resulting senescence could be 
suppressed by blocking DNA repair response (Bartkova et al., 2006). Importantly, DNA 
damage repair prompts the expression of NKG2D ligands, which are recognized by the 
immune system natural killer (NK) cells, triggering the recognition and eradication of 
incipient tumor cells (Gasser et al., 2005). As Tp53 is an upstream inducer of DNA damage 
repair (Levine, 1997), one may envisage here another mechanism to select for Tp53-deficient 
cells in early neoplastic lesions. 
www.intechopen.com
 
DNA Repair and Human Health 
 
192 
It turns out that most cancer cell types undergo a genetic reprogramming to bypass 
senescence, initially through inactivation of cell cycle guardians and later by telomerase 
activation. But how do they escape cell death that usually results from severe genomic 
damage? Remarkably, cancer cells evade apoptosis by short-circuiting this process at several 
stages. Mutations in FAS, whose gene product is a receptor that induces apoptosis upon 
interaction with the FAS ligand, have been associated with human lymphomas (Gronbaek et 
al., 1998), whereas mutations that compromise Tp53 function, thus intracellular stress-
induced apoptosis, are documented for a wide range of human cancers (Hollstein et al., 
1991). Moreover, gene expression may also be altered in order to further the expression of 
protector proteins, like BCL-xL (Foreman et al., 1996) or to decrease levels of pro-apoptotic 
proteins, such as the tumor suppressors BAX and BAK (Degenhardt et al., 2002). Similarly, 
the constitutive activity of MAPK cascade drives the inhibitory phosphorylation of the 
apoptosis agonists BAD (Zha et al., 1996) and BIM (Ley et al., 2003). In addition, a protein 
capable of associating with processed caspase-9, blocking the activation of downstream 
effector caspases, has been observed in non-small cell lung cancer (Yang et al., 2003). 
3.4 The onset of a tumor: Neovascularization, invasion and metastasis 
A solid tumor comprises a heterogeneous assembly of cell subpopulations whose 
progression is dependent on the successful summoning of new vessels in order to replenish 
the tumor mass with oxygen and carbon sources (Folkman, 2003). Actually, the term cancer 
was probably coined to reflect similarities between the thick neovasculature that develops in 
later stages of tumorigenesis and the claws of a crab (Feinberg et al., 2006).  
 In mammalian cells, in situ hypoxia stabilizes hypoxia-inducible factor (HIF)-1ǂ. HIF-1α 
then dimerizes with HIF-1ǃ, forming a potent transcription factor, which is abnormally 
active in cancers (Dang et al., 2008). This increased activity can result both from normal, 
physiological stimuli, i.e., the diminished oxygen tension in peri-necrotic areas of tumors 
(Dachs et al., 1997), and from mutations in growth-associated genes. Indeed, oxygen-
independent activation of HIF or its downstream responsive genes by loss of tumor 
suppressor activity or gain of oncogene function is a common feature in neoplastic lesions: 
loss of PTEN (Zundel et al., 2000) or Tp53 (Ravi et al., 2000), or, on the other hand, 
overexpression of H-RAS (Chen et al., 2001), v-SRC (Jiang et al., 1998) or c-MYC (Shim et al., 
1997), have all been described to amplify HIF response, suggesting that HIF may be a 
keystone gene of malignant progression. In fact, the pleiotropic action of HIF-1 is a key part 
of cancer strategy to thrive and vanquish surrounding tissues. First, its activity is 
responsible for the transcriptional activation of angiogenic factors (Ikeda et al., 1995), 
essential in the recruitment of new blood vessels to drive tumor growth. Furthermore, it also 
triggers the degradation of extracellular matrix (ECM) by the action of metalloproteinases 
(Pouyssegur et al., 2006). This activity, concomitant with a conspicuous decrease in pH 
achieved by the abnormal metabolism of tumors (Gatenby & Gillies, 2004; Ferreira, 2010), 
sets the stage for cancer invasion.  
Until rather recently, the mechanisms by which neoplastic tissues acquire their abnormal 
morphology and plasticity remained essentially mysterious. Nowadays, there is a growing 
perception that an epithelial-to-mesenchymal transition (EMT) may undergird cancer cell 
biological properties. This complex genetic reprogramming, essential in normal 
development, is thought to be responsible for the presence of mesenchymal populations in 
malignant tumors (Thiery & Sleeman, 2006). Strikingly, a recent breakthrough has shown 
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that the malignant cells responsible for metastasis are exactly the ones that have undergone 
EMT in the solid tumor, presenting both self-renewal capacity and enhanced motility (Mani 
et al., 2008). In the context of a solid tumor, HIF-1 may be the main responsible for 
orchestrating this concerted change of cell type through blockade of E-cadherin expression 
(Imai et al., 2003).        
Altogether, this strongly suggests that a new integrative approach to the study of genomics 
may provide valuable insights not only for cancer, but also for other relevant maladies and 
even to normal organismal homeostasis. We shall see throughout the text the key role of 
DNA damage and repair dynamics in the inception, maintenance and exacerbation of a 
malignant phenotype.  
4. DNA repair and misrepair in cancer: When the remedy is worse than the 
disease  
Life as we know it would not be possible without the existence of DNA repair mechanisms. 
If DNA lesions were to accumulate, it is probable that no specialized cellular functions 
would have evolved, due to high inconstancies in the proteins’ composition. Thus, it comes 
as no surprise that all living organisms have developed mechanisms to detect DNA lesions, 
signal their presence and promote their repair. These mechanisms, collectively termed the 
DNA-damage response (DDR), must be sufficiently accurate and efficient to preserve 
genome integrity. Interestingly, some of the key enzymes involved in DNA repair are highly 
conserved from bacteria to man (Hoeijmakers, 2001; Mellon, 2005). A refined set of 
surveillance and regulatory mechanisms, termed cell cycle checkpoints, controlled by a 
highly organized signal transduction network, ensures that, during each cell cycle, DNA 
replication and chromosomal segregation are orderly completed and genome fidelity is 
maintained (Harbour & Dean, 2000; Levine, 1997). DNA repair plays also a crucial role in 
aging and in a variety of human diseases. For instance, defects in various DNA repair 
pathways in hereditary diseases have been linked to the predisposition to a number of 
cancers (Heinen et al., 2002) (section 5). 
The importance of DNA repair dynamics in cancer biology became evident as early as the 
1970s, when it was observed that mice treated with 4-nitroquinoline 1-oxide (4NQO), a 
chemical mutagen, displayed increased mortality and reduced incidence of tumors if treated 
with caffeine, up to five days after treatment with 4NQO (Kondo, 1977). Caffeine is now 
known to inhibit ATM and ATR kinases and, hence, DDR (Sarkaria et al., 1999). These 
results suggested that 4NQO-induced damage in template DNA would occasionally be 
perpetuated during DNA synthesis, thereby indicating that carcinogenesis relies on the 
inheritance of damaged DNA through cell divisions. On the contrary, the inhibition of ATM 
and ATR-mediated error-prone translesion repair by caffeine selectively killed premalignant 
cells. A myriad of DNA repair mechanisms may be subverted during carcinogenesis, 
fostering the achievement of a fully malignant phenotype. Thus, one may envisage a cellular 
reprogramming of genomic maintenance towards augmented DNA misrepair as a driving 
force in tumorigenesis, favoring the progressive arising of clonal populations of cancer cells 
with higher genomic instability. This emerging feature doubtlessly possesses a highly 
malignant potential (Hanahan & Weinberg, 2011). The resultant hyper mutational 
phenotype then undergirds the stepwise acquisition of malignant traits in a Darwinian 
fashion (Fearon & Vogelstein, 1990). 
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4.1 Nucleotide excision repair 
Nucleotide excision repair (NER) is a guardian against topological distortions in DNA, such 
as those induced by the CPDs resultant from UV radiation (section 2) (de Laat et al., 1999). It 
comprises several steps, including lesion recognition, opening of the double helix around 
the damage, excision of the DNA fragment carrying the adduct and polymerization of a new 
fragment, followed by its ligation (Mu et al., 1996). At least 16 different proteins are 
involved, including the XP proteins (groups A to G), named after the syndrome that is 
caused by their deficiency, Xeroderma pigmentosum (XP). This syndrome is characterized by 
hypersensitivity to UV radiation and a predisposition to skin cancer (Evans et al., 1997).  
The NER pathway has been divided into two sub-circuits: global genome repair (GGR), 
which repairs DNA lesions independently of their location in the genome, and transcription-
coupled repair (TCR), which acts upon lesions in regions involved in transcription. In both 
cases, the unfolding of the double DNA helix is assured by helicases XPD (3’-5’ polarity) and 
XPB (5’-3’ polarity) (Scharer, 2003). This process renders the lesion accessible to 
endonuclease XPG, which, in conjunction with helicase XPA, recognizes the lesion and 
cleaves the nucleotide at its 3’ edge. Next, endonuclease XPF, in association with ERCC1 
(excision repair cross-complementation group 1), removes the damaged nucleotide from the 
5’ edge of the damaged chain and liberates a fragment of 24–32 bases. Finally, a complex of 
DNA polymerases and ligases is recruited to restore normal nucleotide sequence in the 
damaged chain (Friedberg, 2001).  
TCR, which is triggered by RNA polymerase arrest at sites of DNA distortion (Lainé & Egly, 
2006), was discovered following early key observations that CPDs were more efficiently 
removed from actively transcribed genes (Bohr et al., 1985). One could envisage TCR 
overactivity as a strategy for cancer cell propagation, as rapidly dividing cells are 
particularly exposed to transcriptional stress and damage of active genes is a cell cycle-
independent potent inducer of Tp53 accumulation and subsequent apoptosis (Yamaizumi & 
Sugano, 1994). This hypothesis finds support in the fact that cisplatin, a common anticancer 
drug that forms cross-links with DNA capable of stalling RNA polymerase (Tornaletti et al., 
2003), is most effective in TCR-deficient carcinoma cell lines (Stubbert et al., 2010). Studies 
using transgenic mice deficient in either TCR or GGR (Berg et al., 2000) and mouse 
embryonic stem cells (de Waard et al., 2008), both valuable models for key malignant cell 
subpopulations within tumors (Wong et al., 2008), strongly suggest that hampering GGR has 
even greater carcinogenic potential than hampering TCR. As GGR does not depend on gene 
expression, these findings led some authors to put forward the hypothesis that the greater 
oncogenic potential of GGR loss over TCR loss resides in the fact that, albeit both losses 
facilitate mutations in essential growth-related genes, GGR ablation would awaken inactive 
proto-oncogenes with simultaneous mutational inactivation of actively transcribed tumor 
suppressor genes, while TCR ablation would silence active tumor suppressor genes, with a 
concomitant increase in Tp53-dependent apoptosis (Berg et al., 2000). In fact, Tp53 null 
human fibroblasts display a defalcation in GGR and reduction in their overall capacity of 
repairing CPDs, but normal TCR activity and even an improved resistance against UV 
cytotoxicity (Ford & Hanawalt, 1995).  
Inter-individual variation in lung cancer susceptibility may be modulated in part by single-
nucelotide polymorphisms (SNPs) in NER genes. For instance, SNPs in XPC and XPD 
increased lung cancer risk in Northern Spain and Chinese populations (Lopez-Cima et al., 
2007; Xing et al., 2003). Additionally, interactions between XPC/XRCC3 and XPD/XRCC3 
polymorphisms were observed, suggesting that coordination between NER and BER repair 
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pathways contribute to the individual susceptibility to develop cancer (Lopez-Cima et al., 
2007). Impressively, it was reported that SNPs in NER genes modified the relation between 
breast cancer and smoking among African Americans and Caucasians, albeit with some 
differences (Mechanic et al., 2006). Some studies also suggest that polymorphisms on ERCC1 
and ERCC2, two NER genes, may influence risk of glioma (Wrensch et al., 2005). In addition, 
some minor allele variants of ERCC4 and BRIP1 (BRCA1-interacting protein 1) have been 
reported to increase meningioma risk, while variants of ERCC2 and ERCC5 augmented 
acoustic neuroma risk (Rajaraman et al., 2010). Finally, XPD/ERCC2 SNP rs13181 variant 
carriers display higher cutaneous melanoma risk (Mocellin et al., 2009). 
4.2 Translesion synthesis  
Distortions in the DNA double helix pose problems not only to transcription, but also to 
replication. However, during evolution, cells have acquired a considerable number  
of DNA polymerases able to bypass CPDs and other obstacles in a process named  
DNA translesion synthesis (TLS) (Goodman & Tippin, 2000). TLS is essential for normal 
physiology, and alterations in genes coding TLS polymerases are associated with medical 
conditions such as XP (Masutani et al., 1999). It also provides a paragon of a DNA repair 
pathway that may be used by cancer cells for their benefit: recent experiments  
where several cycles of tumor engraftment and treatment with an anticancer drug were 
carried out have clearly shown that TLS activity drives drug resistance in tumors  
in vivo (Xie et al., 2010b).  
4.3 Mismatch repair  
MMR is a DNA repair system that recognizes a wide range of genetic lesions, such as 
insertions, deletions and base mismatches introduced during DNA replication (Larrea et al., 
2010). MMR proteins were proposed to act as direct sensors of DNA damage by helping to 
recruit ATR (ATM and Rad3-related), a phosphoinositide 3-kinase-related kinase (PIKK) 
implicated in responding to several DNA lesions and stalled replication forks, to sites of 
DNA damage, triggering the intra-S phase checkpoint (Abraham, 2004; Choi et al., 2010; 
Yoshioka et al., 2006). Mismatch recognition is carried out by the MutSα (MSH2/MSH6) and 
MutSβ (MSH2/MSH3) heterodimers, which recognize all eight single nucleotide 
mismatches, as well as small insertion/deletion loop (IDL)-type structures. Following 
recognition by these heterodimers, MUTL homologue heterodimers (MLH/PMS) are 
recruited and a necessary single-strand scission (nick) is introduced at either the 3’ or 5’ side 
of the mismatch by a 5’-exonuclease and some MLH members. The minimal 5’→3’ and 
3’→5’ excision reaction requires hMSH2/hMSH6 (or hMSH2/hMSH3), hMLH1/hPMS2, 
EXOI, RPA, PCNA, and RFC, while re-synthesis of the single-stranded gap is carried out by 
DNA polymerase δ (Polδ) and DNA ligase I (Larrea et al., 2010). 
In the context of oncology, MMR is best known for increased frameshift mutation rates 
(commonly called microsatellite instability (MSI or MSI-H)) caused by its deficiency, 
characteristic of various human malignancies (Oda et al., 2005). It thus comes as no surprise 
that proteins involved in this pathway display properties of tumor suppressors. For 
instance, MSH2 has been recently described to abrogate mutations adjuvant of oncogenic c-
MYC activity in early lymphomagenesis (Nepal et al., 2009). Strikingly, breakthrough 
findings of fifteen years ago have established that chromosomal transfer designed to correct 
MMR defects in human tumor cells can also bypass TCR deficiency, establishing an 
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unequivocal link between NER and MMR pathways (Mellon et al., 1996). Nonetheless, little 
is known about this still hotly debated interaction (Kobayashi et al., 2005). 
In humans, defects in MMR genes confer a strong predisposition to hereditary nonpolyposis 
colorectal cancer (HNPCC), also known as Lynch syndrome (LS), and associated 
endometrial cancer. Moreover, epigenetic silencing of some MMR genes may contribute to 
the development of 5 to 15% of sporadic cancers with a microsatellite instability-high (MSI-
H) phenotype (Peltomaki, 2003). MMR-deficient colorectal cancers (CRCs) have distinct 
features from other CRC types, such as MSI, multi-focality, increased likelihood of right-
sided colon cancer location, mucinous histology and the presence of a Crohn's-like 
lymphocytic infiltrate (Greenson et al., 2003; Jenkins et al., 2007). In addition, MSI-H tumors 
also display multiple defects in other genes containing microsatellite repeats, such as those 
governing growth signaling (Markowitz et al., 1995), apoptosis (Rampino et al., 1997) and 
transcriptional activation (Duval et al., 1999).  
Three distinct genetic mechanisms are proposed for the onset of MMR-deficient CRCs. First, 
monoallelic germline MMR mutations and somatic loss of the second MMR allele cause 
HNPCC. LS carrier tissues are MMR-proficient, but when the second MMR gene allele is 
lost in some somatic cells, they become MMR-deficient and give rise to either CRC, small 
bowel, urethra, renal, pelvis, biliary tract, brain, gastric or ovarian cancers. HNPCC is 
clinically heterogeneous, depending on which of the MMR genes is affected, being 
classically associated with heterozygous MLH1, MSH2, MSH6 and PMS2 loss-of-function 
mutations. Recently, variants of the MSH3 gene were proposed as low risk alleles, 
contributing to colon cancer risk in LS families when associated with other low risk alleles. 
Interestingly, some surveys indicate that the spectrum of MMR mutations in HNPCC differs 
between China and Western countries (Jin et al., 2008) and even between northern and 
western China (Sheng et al., 2006), suggesting that MMR mutation patterns depend on 
ethnicity. The second mechanism is germline biallelic MMR gene mutations, where all body 
tissues are MMR-deficient. The second mutation is associated with early onset of central 
nervous system (CNS) tumors, hematological malignancies and gastrointestinal neoplasia, 
as well as autoimmune disorders (Barnetson et al., 2006; Felton et al., 2007; Lindor et al., 
2005). Finally, both MMR alleles can be mutated or epigenetically inactivated in some cells, 
causing de novo sporadic MMR-deficient CRCs, which account for ca. 12.5% of CRCs 
(Barnetson et al., 2006). MLH1 promoter hypermethylation is the most common cause of 
sporadic MMR-deficient CRCs (Shen & Issa, 2002). In recent years, constitutional 
epimutations of MLH1 and, more seldom, of MSH2 have been identified in various 
mutation-negative HNPCC cases. In contrast to genetic mutations, MLH1 epimutations are 
reversible between generations and thus display non-Mendelian inheritance, suggesting that 
these epimutations can be reversed in the gametes and re-established in the somatic cells in 
successive generations. Still, the molecular profile of tumors from individuals with 
constitutional MLH1 epimutations is similar to those of individuals with conventional 
sequence mutations of MLH1, i.e. tumors with MSI and loss of the MLH1 protein (Hitchins 
& Ward, 2009).  
4.4 Base excision repair      
ROS are simultaneously a conspicuous byproduct of our metabolism, key molecules in 
signaling pathways and a major source of DNA damage (section 2). Albeit their function 
drastically depends upon their concentration and the cell type and environment where they 
occur (Hussain et al., 2003), cancers in general display constitutive oxidative stress 
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(Toyokuni et al., 1995). A direct consequence of oxidative stress is the infliction of mutations 
in DNA (Cooke et al., 2003), which, when coupled with altered DNA repair mechanisms, set 
the stage for stepwise malignization. The main cellular machinery involved in fixing ROS-
induced oxidative DNA damage is the ubiquitous BER. Although some experiments suggest 
that the aforementioned TCR may also be involved in the repair of oxidative DNA lesions, 
this field is currently under intense debate, as assessed by the retraction of several articles 
(Mellon, 2005). Components of the BER pathway constitute a versatile line of defense 
against not only DNA oxidative damage, but also SSBs and other small, non-helix-distorting 
lesions. It is initiated by damage-specific DNA glycosylases, which create abasic sites by 
cleaving the N-glycosidic bond (Hitomi et al., 2007). AP endonuclease then recognizes AP 
sites and cleaves the DNA phosphodiester backbone, leaving a 3’-hydroxyl group and a 5’-
deoxyribose phosphate group flanking the nucleotide gap. Poly(ADP-ribose) polymerase 1 
(PARP1), together with PARP2 and poly(ADP-ribose) glycohydrolase (PARG), recognizes 
the DNA strand interruption and facilitates the recruitment of specific BER proteins, 
including the BER scaffold protein XRCC1 and DNA polymerase β (Polβ) (Almeida & Sobol, 
2007a; Sobol et al., 2000). Subsequently, the repair proceeds by two sub-pathways initiated 
by Polβ: short-patch (SN) BER repairs one nucleotide, while long-patch (LP) BER repairs 2 to 
15 nucleotides. Albeit different subsets of enzymes are used, there is cooperation between 
the two sub-pathways (Hitomi et al., 2007). 
If left alone, most ROS-induced lesions, such as oxidized bases and abasic sites (Cooke et al., 
2003), could be replicated by either normal replication or TLS (Goodman & Tippin, 2000). 
Misreplication of oxidized bases and non-instructional AP sites would often give rise to 
point and, sometimes, more complex mutations; SNPs, which are frequently observed (1 in 
300 bp) in mammalian genomes, likely result from such mutations. Point mutations in 
growth-related genes can drive carcinogenesis (Fearon & Vogelstein, 1990), and certain 
SNPs in DNA repair genes impart greater cancer susceptibility (Goode et al., 2002).  
Several reports have confirmed the relationship between SNPs in BER genes and cancer 
susceptibility (Hung et al., 2005). Particularly, polymorphisms on hOGG1 and XRCC1 genes 
are associated with lung, esophagus, stomach and nasopharyngeal (NPC) cancer risk. 
Similarly to MMR, SNP occurrence in BER genes appears to be dependent on ethnicity: 
single nucleotide changes at codons 194, 280 and 399 of XRCC1 were associated with risk of 
several types of gastrointestinal, bladder, breast and lung cancers in the Japanese population 
(Arizono et al., 2008), while SNPs in hOGG1 codon 326 correlated with increased NPC and 
gallbladder risk in Southern Chinese populations (Cao et al., 2006; Jiao et al., 2007). The APE1 
Asp148Glu polymorphism is highly predictive for lung cancer in Caucasians, and 
cumulative cigarette smoking modifies the associations between XRCC1 Arg399Gln and 
XPD Lys751Gln polymorphisms and lung cancer risk in nonsmokers and light smokers (de 
Ruyck et al., 2007). Relevant epimutations also occur in BER genes, such as aberrant 
methylation of XRCC1, which contributes to gastric carcinogenesis (Wang et al., 2010).  
4.5 Non-homologous end-joining and homologous recombination  
Despite the existence of some very specific scenarios where cleavage of both strands of the 
DNA molecule is essential, such as in recombination of some immune system genes (Jeggo 
et al., 1995), DSBs are particularly genotoxic. DSBs usually result from insults such as X- or 
gamma rays or topoisomerase poisons, or simply arise when a replication fork encounters 
damaged DNA (Hartlerode & Scully, 2009). DSB repair takes place in vivo within defined 
foci characterized by a distinctive histone phosphorylation (Ǆ‐H2AX), accumulation of auto-
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phosphorylated DNA‐PKcs and recruitment of repair and signaling proteins, including 
53BP1, NFBD1/MDC1 and the chromatin‐bound form of the MRE11/RAD50/NBS1 
complex (Chan et al., 2002a; Lou et al., 2003; Mirzoeva & Petrini, 2001; Paull et al., 2000; 
Schultz et al., 2000; Shang et al., 2003). Two mechanisms have evolved to remediate this type 
of damage: non-homologous end joining (NHEJ) and homologous recombination (HR) 
(Hartlerode & Scully, 2009). 
Ku70, DNA-protein kinase catalytic subunit (DNA-PKcs), XRCC4, DNA ligase IV and 
Ku86/XRCC5 are the major proteins involved in NHEJ. Curiously, some Ku86 truncated C-
terminus variants (Ku86v) with decreased Ku-DNA end binding and DNA-PKcs activities 
have been reported in human myeloma cells and associated with augmented chemo- and 
radiotherapy sensitivity (Tai et al., 2000). The higher sensitivity of Ku86V-portraying cells 
may result from compromised DNA repair ability, making this gene a novel therapeutic 
target in cancer (Tai et al., 2000).  
A statistically significant correlation between three Ku86/XRCC5 polymorphisms, one XRCC6 
tSNP and a single-locus variant at the DNA ligase IV SNP2 and the risk to develop gliomas has 
recently been established (Liu et al., 2007). Moreover, an haplotype analysis performed in 
samples from glioma patients also recognized genetic variants in XRCC4 as risk predictors and 
identified a three-locus interaction involving DNA ligase IV SNP4 rs1805388:C>T, XRCC4 
SNP12 rs7734849:A>T and SNP15 rs1056503:G>T as a common feature of these tumors (Liu et 
al., 2007). A significant association between XRCC4 (rs1805377) and DNA ligase IV (rs1805388) 
genotypes was also observed among non-small cell lung cancer (NSCLC) patients, of which 
those who had a homozygous variant guanine/guanine genotype of the XRCC4 gene were 
given a poorer prognosis (Tseng et al., 2009). 
NHEJ overactivity has been implicated in human myeloid leukemia pathogenesis (Gaymes 
et al., 2002), a cancer type marked by chromosomal aberrations, namely the Philadelphia 
translocation (sections 1 and 2) (Nowell, 2007). More precisely, this DNA repair 
deregulation, which seems to be present in both the acute and chronic forms of the disease, 
leads to conspicuous misrepair of DSBs, resulting in deletions of up to 400 bp. Ku70/Ku86, a 
protein heterodimer that binds free ends at a DSB (Mimori & Hardin, 1986), was implicated 
in repair infidelity, suggesting that alterations in this complex drive genomic instability in 
myeloid leukemia (Gaymes et al., 2002). 
HR is a cell-cycle dependent DNA repair pathway, as it normally relies on sister chromatids 
to perform error-free repair of DSBs (Richardson et al., 1998). Similarly to NHEJ, which is 
instrumental in immune cell development (Jeggo et al., 1995), HR also performs an 
important role in cell physiology, as it provides an alternative strategy for telomere length 
maintenance (Dunham et al., 2000), as already mentioned in section 3. HR uses the RAD50, 
BRCA1 and BRCA2 protein families, as well as XRCC3, a member of the RECA/RAD51-
related protein family. It can be divided essentially in two sub-pathways: in homology-
directed repair (HDR), a homologous sequence in a sister chromatid is used to fix the 
damaged sequence, whereas in single-strand annealing (SSA), single strands of the same 
helix undergo annealing. This can happen in repetitive regions of DNA, leading to loss of 
information and may be considered as especially mutagenic if one bears in mind that ca. 
50% of our genome is constituted by such sequence repeats (International Human Genome 
Consortium, 2001). 
At first glance, it is not clear-cut whether prompt HR activity is advantageous for cancer 
cells or not. Remarkably, transcriptional repression of RAD51, a key player in HR (Sung et 
al., 2003), is known to occur in several tumor types in response to their hypoxic environment 
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(Bindra et al., 2004). In addition, mutations in HR genes do correlate with notable 
chromosome rearrangements (Patel et al., 1998). Nonetheless, recombinational activity may 
also enhance anticancer drug resistance (Hansen et al., 2003) and prevent telomere erosion 
(Dunham et al., 2000), which may be valuable in aggressively dividing malignant cells. 
135G>C of RAD51, as well as Arg188His and Thr241Met of XRCC3 have recently been 
pointed as potential polygenic causes of CRC occurrence, and their screening has been 
suggested (Krupa et al., 2011a). As the RAD51 polymorphism implicates a lower level of 
RAD51 protein, and consequently of other proteins such as XRCC2 and XRCC3, it may 
explain the lower DSB repair capacity observed in CRC. Curiously, the same genetic hits 
have been observed in endometrial cancer and considered as an additional marker of the 
disease (Krupa et al., 2011b). Although germline mutations in BRCA1 and BRCA2 have been 
vastly referred to confer higher risk of breast cancer development, recent evidence suggests 
that this risk is modified by other genetic or environmental factors that cluster in families. A 
recent genome-wide association study showed that common alleles at SNPs in FGFR2, 
TNRC9 and MAP3K are also associated with increased breast cancer risk in the general 
population and in BRCA1 and BRCA2 mutation carriers. The different effects of FGFR2 and 
MAP3K1 SNPs in BRCA1 and BRCA2 carriers result in breast cancer tumors with an 
additional distinct nature (Antoniou et al., 2010). 
HR can compete with NHEJ for DSB repair: recent studies in yeast have shown that 
phosphorylation of SAE2, known to be involved in processing meiotic and mitotic DSB, by a 
CDK, functions as a regulator of the relative activity of NHEJ and HR after DSB resection 
(Huertas et al., 2008). This coordination is of utmost importance, as HR activity during G1 
would lead to the use of an allele as a template to the damaged one and, thus, to loss of 
heterozygosity, potentially unveiling mutations in tumor suppressor genes during the 
oncogenic process. In addition, it has been observed that RAD51 impairment imparts 
mutagenicity to recombinational repair (Stark et al., 2004). 
4.6 Fanconi Anemia/BRCA pathway  
Fanconi anemia (FA) is a genetic disease characterized by genomic instability, checkpoint 
arrest and cancer predisposition. Affected patients can develop various congenital 
abnormalities, including short stature, bone marrow failure during childhood and particular 
predisposition to myelodysplasia, acute myeloid leukemia and head and neck cancers (de 
Winter & Joenje, 2009). A network of at least 13 genes, designated FANCA to FANCN, is 
critical for maintaining chromosomal integrity (Thompson, 2005). Indeed, FA can be caused 
by mutations in any one of these genes (Mathew, 2006). 
Although their molecular function is not completely understood, all FA proteins contribute 
to processing ICLs. Consequently, ICL induction in the absence of FA proteins leads to 
reduced cell viability and an accumulation of cells with a 4N DNA content, representing 
cells in either late S or G2/M (Thompson, 2005). FA proteins interact in the FANC/BRCA 
pathway, in which a pivotal event is the monoubiquitination of FANCD2 (de Winter & 
Joenje, 2009). This monoubiquitination requires the FA nuclear core complex, formed by 
several FA proteins. BRCA2/FANCD1, PALB2/FANCN and FANCJ proteins are not 
required for this event and are considered downstream of FANCD2 monoubiquitination. 
The FANC/BRCA pathway is interconnected with HR and NHEJ systems and its disruption 
provokes the clinical and cellular abnormalities common to all FA subtypes (Wang & 
D'andrea, 2004).  
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Remarkably, some genetic mutations associated with FA are also associated with hereditary 
breast cancer. For example, FANCD1, the gene defective in the FA-D1 patient 
complementation group, was found to be the hereditary breast cancer gene BRCA2 (Howlett 
et al., 2002). Likewise, FANCJ (also called BACH1/BRIP1), which was identified as the gene 
defective in the FANCJ-null (FA-J) patient complementation group (Levitus et al., 2005), was 
initially linked to hereditary breast cancer (Cantor et al., 2004). FA patients that carry 
mutations in BRCA2 only (de Winter & Joenje, 2009) differ from others in presenting much 
more severe phenotypes, with early-onset and high rates of leukemia and some solid tumors 
(Howlett et al., 2002). 
5. DNA repair in anti-cancer therapy: A double-edged sword 
Chemotherapeutic drugs used in cancer treatment frequently take advantage of the intrinsic 
instability of the genome to inflict damage in the DNA of both healthy and tumor cells. 
Depending on their mechanisms of action and pharmacological properties, these drugs may 
be more genotoxic towards tumor cells than towards healthy ones. These agents include 
nitrosureas (carmustine, lomustine, fotemustine, streptozokine), tetrazines (temozolamide, 
dacarbazine), aziridines (thiotepa, mitomycin C), bischloroethylamines (melphalan, 
chlorambucil), DNA topo-isomerases I and II inhibitors (camptothecins and 
epipodophyllotoxins) and, notably, platinum complexes (cisplatin, carboplatin, oxaliplatin) 
(Bignami et al., 2000; Wang, 1996). 
5.1 Chemotherapeutic drugs and DNA repair systems 
The outcome of cancer patients following chemo- and radiotherapy is mostly determined by 
DNA damage responses to the treatments, by both malignant and normal cells. As 
mentioned before, some of the long succession of random mutations that typically give rise 
to human cancers occur in determinant genes of important repair and survival pathways. In 
parallel with epigenetic changes either in DNA and/or histones, these mutations drive 
tumorigenesis (Esteller, 2008; Santella et al., 2005). As such, cancer treatments that target a 
specific DNA repair defect can be selectively toxic to cancer cells exhibiting that defect, 
while sparing normal, DNA repair-proficient cells. Extreme care must, however, be exerted, 
as genetic and epigenetic perturbations of MMR and BER pathways, following the use of 
alkylating/antimetabolite chemotherapeutics and/or ionizing radiation, were associated 
with the onset of new cancers (David et al., 2007; Iyer et al., 2006; Jiricny, 2006; Karran & 
Attard, 2008; O'Brien & Brown, 2006). An increased understanding of how MMR and/or 
BER DNA repair pathways influence the cytotoxicity of chemotherapeutic drugs and/or 
ionizing radiation treatments in both normal and malignant tissues led to an important 
therapeutic distinction between these two DNA repair pathways, i.e., whereas MMR 
processing is required for the cytotoxicity of drug treatments, BER processing sometimes 
leads to reduced drug-related cytotoxicity. A similar distinction can be made for ionizing 
radiation damage processing by MMR versus BER, even though NHEJ and HR repair 
systems are the dominant pathways to repair DSBs induced by ionizing radiation (Matsuoka 
et al., 2007; Workman et al., 2006). 
5.1.1 Tp53, the central player in DNA repair systems  
Tp53 is a master pleiotropic guardian of genome integrity, being a key node in several 
pathways of the DNA repair circuitry that must be subverted during carcinogenesis. 
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Radiotherapy and most chemotherapeutic agents directly target DNA and, as a 
consequence, activate DNA repair processes and/or cell cycle arrest. Tp53 coordinates such 
functions, as it participates in the main DNA repair systems. Mutations within the tumor 
suppressor Tp53 gene are highly frequent in human tumors and commonly associated with 
a resistance phenotype. 
In cells with wild type Tp53, cisplatin resistance can be overridden by several mechanisms 
involving this protein, namely its direct interaction with proteins involved in cisplatin 
resistance and their targeting for proteasomal degradation, this way increasing cellular 
sensitivity to the drug (Abedini et al., 2008). Other mechanism can involve up-regulation of 
Tp53 in response to PTEN overexpression (Yan et al., 2006) and enhanced Tp53-dependent 
apoptosis due to XIAP expression silencing (Fraser et al., 2003). In contrast, decreased Tp53 
phosphorylation, in the presence of active AKT, drives a decrease in cisplatin-induced cell 
death (Fraser et al., 2008). 
It has been shown that a combination of Tp53 inactivation and MMR deficiency results in 
cisplatin resistance (Lin & Howell, 2006). Paradoxally, loss of Tp53 and/or MMR is a 
common event in cancers following treatment with cisplatin and its analogues (Fink et al., 
1998; Lin & Howell, 2006).  
5.1.2 Overcoming Tp53 deficiency 
The absence of wild type Tp53 in some tumor cells can be exploited therapeutically through 
the use of antagonistic drugs (Blagosklonny, 2002). An example is taxol, a ǃ-tubulin target 
agent which simultaneously kills and/or blocks Tp53 deficient cancer cells during mitosis 
and arrests wild type cells in G1 or G2 phases (Demidenko et al., 2008). Taking advantage of 
taxol specificity, its use in association with other mitotic and genotoxic drugs is frequent 
(Blagosklonny et al., 2000). However, the usefulness of mitotic chemotherapeutics is limited 
by their ability to activate Tp53-independent checkpoint mechanism in cancer cells with 
mutant Tp53 (Blagosklonny, 2002).  
Recently, the MDM2 antagonist Nutlin-3 was reported to selectively activate Tp53 pathway, 
inducing cell cycle arrest of Tp53 wild type non-small cell lung cancer (NSCLC) cells, while 
taxol selectively killed Tp53 deficient pharyngeal squamous-cell carcinoma cells (Tokalov & 
Abolmaali, 2010). Moreover, modulators of Nutlin-3 might also offer a new therapeutic 
option for patients with tumors expressing wild type Tp53, either in mono (Vassilev, 2005) 
or combined therapy (Kojima et al., 2005). Inhibition of the Tp53-MDM2 interaction has been 
documented following nutlins administration in multiple types of cultured cells, with a high 
degree of specificity. The consequences are, generally, Tp53 stabilization induction, p21 
induction, cell cycle arrest in G1 and G2 phases, apoptosis and growth inhibition of 
proliferating cancer cells (Vassilev et al., 2004). It is interesting that nude mice treatment 
with Nutlin-3 inhibits tumor growth without overt toxicity, suggesting that normal tissues 
may have higher tolerance to Tp53 activation (Vassilev, 2007). Thus, depending on the 
genetic status of the tumor, Nutlin-3 might be administrated in monotherapy, for the 
activation of the Tp53 pathway, or in combination with taxol, for the protection of the 
surrounding normal tissue. The study of Nutlin-3 biodistribution in the body may be critical 
for the understanding of its pharmacodynamics and therapeutic effects in vivo. 
Other strategies to overcome Tp53 mutant-dependent cancer cell resistance to certain 
anticancer drugs have been proposed. Reactivation of mutant Tp53 using small molecular 
therapeutic agents that change mutant Tp53 conformation or depletion of mutant Tp53 with 
Hsp90-active agents (e.g., geldanamycin) has been attempted (Fojo, 2002; Selivanova, 2001). 
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Yet, although depletion of mutant Tp53 per se cannot restore Tp53 functions, it may abolish 
dominant-positive effects (Wang et al., 2003). A final strategy includes the use of the histone 
deacetylase inhibitor FR901228 (FK228) (Sandor et al., 2002), a depsipeptide expected to be 
predominantly cytotoxic to Tp53 proficient cells, as it inhibits the trans-activating functions 
of wild type Tp53 (Juan et al., 2000). However, recent studies unexpectedly revealed that 
FK228 was less active in Tp53 proficient cells (Blagosklonny et al., 2002; Kitazono et al., 2002) 
as its association with trichostatin A induced Tp53-regulated transcription in cells with 
mutant Tp53, resulting in complete depletion of the Tp53 protein. Restoring or mimicking 
Tp53 trans-functions appears to be highly cytotoxic to cells with mutant Tp53. Yet, care 
must be taken, since histone deacetylase inhibitors are cytotoxic to both normal and tumor 
cells with both wild type and mutant Tp53 (Blagosklonny et al., 2005). 
5.2 Combined therapies to overcome chemo- and radio-resistance  
MMR is now accepted to be fundamental for the processing of the DNA damage induced by 
several classes of chemotherapeutic drugs (Seifert & Reichrath, 2006). The exact mechanisms 
that drive MMR activity are still not clear and two models – the futile cycle model and the 
direct signaling model – have been proposed. Nevertheless, prolonged G2 checkpoint arrest 
is triggered in both models following MMR activation, leading to an activation of some 
apoptotic pathways (Iyer et al., 2006; Jiricny, 2006; O'Brien & Brown, 2006). 
According to the futile cycle model, MMR has a single function with the 
MUTSǂ/MUTLǂ/EXO-1 complex ultimately creating persistent SSBs in the vicinity of 
chemically induced mismatches, as happens in the treatment with N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG) and thioguanine (6-TG). Briefly, when 6-methyl thioguanine 
(me6-TG) or O6-methyl guanine (O6meG) are formed following 6-TG and MNNG 
treatment, respectively, and are in the template during replication, the incorporation of a C 
or T into the newly synthesized strand creates an additional mismatch, as the modified base 
remains in the template strand after MMR-mediated excision (Yoshioka et al., 2006). Repair 
synthesis proceeds with regeneration of O6meG-C or -T mismatches in a repetitive (futile) 
cycle, culminating with a G2 checkpoint arrest, probably mediated, in an initial phase, by 
the Tp53-ATR-CHK1 pathway and, later, by the ATM-CHK2 pathway (Adamson et al., 2005; 
Jiricny, 2006; Yan et al., 2003; Yan et al., 2004). 
Further MMR signaling pathways consistent with futile cycling have been reported after 
administration of other drugs. For example, cisplatin treatment of MMR-proficient cells 
results in the generation of ICLs, which can lead to MMR-related activation of c-JUN and c-
ABL kinases (Gong et al., 1999; Nehme et al., 1999). Additionally, ionizing radiation-induced 
damage also activates MMR, resulting in modest cytotoxicity following acute and high-dose 
exposures. More significant cytotoxicity is only observed with prolonged exposures to low 
doses of radiation (Yan et al., 2001). These observations may be a consequence of activation 
of Tp53-p21 pathways due to prolonged G2 delay, which is eventually followed by 
apoptosis or autophagy.  
In the direct signaling model, MMR has two separate functions: repairing DNA damage and 
transducing the resulting signal (Fishel, 1999; Yoshioka et al., 2006). After MUTSǂ/MUTLǂ 
complex recognition of the chemically induced mispair, it acts as a direct sensor, straightly 
activating the Tp53-ATR-CHK1 pathway (Iyer et al., 2006; Jiricny, 2006). DNA mismatch 
processing through the downstream sub-processes of excision and re-synthesis can then 
follow independently of the damage-induced G2 cell cycle delay.  
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The absence of a functional MMR system confers cells a faulty ability to recognize 
chemotherapy-induced DNA damage and a damage-tolerant phenotype. As a consequence, 
these cells are spared by conventional therapies and accumulate more mutations that boost 
their malignancy (Karran, 2001; Seifert & Reichrath, 2006). For instance, cells with lower 
levels of MSH2 or MLH1 proteins are competent for recognizing damage, but fail to trigger 
checkpoint activation or apoptosis (Cejka et al., 2003; Claij & Te Riele, 2004). In contrast, 
mutations in or near the nucleotide binding site of MSH2 and MSH6 disable MMR, but leave 
intact the apoptotic response to DNA damaging agents (Lin et al., 2004; Yang et al., 2004). 
The importance of MMR proteins on chemotherapy outcome is well evidenced by the role of 
the MSH2 protein in recognizing base pairs involved in modified or damaged bases and, 
consequently, in triggering further MMR-mediated processing at the damaged sites 
(Friedman et al., 2007; Yamada et al., 1997). However, the activation of MSH2 is context 
dependent, as in non-transformed breast cell lines TGF-ǃ activates MSH2 promoter in a 
Tp53-dependent manner, while in Tp53-defficient breast cancer cells, TGF-ǃ down-regulates 
MSH2 expression through a miRNA-mediated mechanism, and confers resistance to DNA-
damaging anticancer agents (Yu et al., 2010).  
The multiplicity of MMR functions in the DNA damage response has been recently 
uncovered through separation-of-function mutations (O'Brien & Brown, 2006). Interestingly, 
newly found deletions in the MLH1 C-terminus (703–725), which is important for 
maintaining the stability of the PMS2 MMR protein, also disrupted the FANCJ/MLH1 
interaction (Mohd et al., 2006), delaying MMR signaling and apoptotic responses. This delay 
provides time for the O6-methylguanine-DNA methyltransferase (MGMT) enzyme to 
reverse DNA methylation and, thus, to confer resistance to agents that induce O6-meG 
lesions. In essence, FANCJ deficiency alters the competition between two pathways: 
MGMT-pro-survival versus MMR-pro-death. A link between FANCJ and HNPCC has also 
been established, providing insight towards directed therapies, as loss of the FANCJ/MLH1 
interaction sensitizes cells to DNA cross-linking agents (Xie et al., 2010a). 
5.2.1 Targeting simultaneously DNA, MMR, NER and Tp53 
Cisplatin is one of the most widely used chemotherapeutic agents (Siddik, 2003). However, its 
clinical use is conditioned by the development of resistance, which can result from reduced 
intracellular accumulation, increased drug inactivation, increased repair of damaged DNA, 
increased activation of pro-survival pathways or inhibition of pathways that promote cell 
death (Siddik, 2003). An intermingling of these factors has also been suggested, justifying the 
difficulty to overcome platinum resistance (Dempke et al., 2000). Defects in Tp53 and MMR 
pathways have been reported to underline cisplatin resistance, both in vitro and in the clinic. In 
agreement, loss of action of the MMR system can result in increased resistance to cisplatin, as 
cells are allowed to replicate damaged DNA instead of entering an apoptotic program (Martin 
et al., 2008; Siddik, 2003; Vaisman et al., 1998; Watanabe et al., 2001). An additional correlation 
between MMR deficiency (due to a BRAF gene mutation), MSI and cisplatin resistance was 
also unveiled using non-seminomatous germ cell tumors (Honecker et al., 2009). 
To overcome cisplatin resistance, combined therapies using gemcitabine (2’-deoxy-2’,2’-
difluorocytidine) and cisplatin have been used (Villella et al., 2004). Attempts to explain 
gemcitabine enhanced cytotoxicity in platinum-resistant endometrial cancer cell lines revealed 
that gemcitabine downregulates MSH2, Tp53 and ERCC1 (the NER protein involved in 
intracellular nucleotide repair) as compared to cisplatin alone (Smith et al., 2006). 
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5.2.2 Targeting simultaneously DNA and MGMT  
DNA alkylation-induced damage is one of the most efficacious anticancer therapeutic 
strategies directed to cancer cells with weakened DNA repair capacity. There is ample 
preclinical evidence that MMR-deficient cancer cells are resistant to both methylating agents 
and some antimetabolites, as 5-fluorouracil (5FU), whereas they are sensitive to oxaliplatin 
and, possibly, even more sensitive to irinotecan (a topoisomerase I inhibitor) (Barratt et al., 
2002; Damia & D'incalci, 2010; Kim et al., 2007; Ribic et al., 2003). In the case of SN1 DNA 
methylating drugs like MNNG, temozolomide (TMZ) or procarbazine, the prevalent DNA 
lesion (O6meG) is largely responsible for their cytotoxicity (Goldmacher et al., 1986; 
Haracska et al., 2000; Karran & Bignami, 1992) and cells deficient in MUTSǂ and MUTLǂ 
activities are highly resistant to killing by these drugs, as O6meG is easily repaired by 
MGMT (Iyer et al., 2006; Kaina et al., 2007). Actually, many colon tumors become resistant to 
DNA-alkylating agents due to overexpression of MGMT or MMR-deficiency (Liu & Gerson, 
2006). In contrast, G:C to G:T transition mutations occur in MGMT-deficient cells, as a result 
of their inability to process O6meG during DNA synthesis (Kawate et al., 1998). In MMR-
proficient cells, G:T mismatches are easily repaired (Branch et al., 1993). However, if the 
O6meG is not repaired before the re-synthesis step, it is believed that the repetitive cycle of 
futile MMR will generate tertiary lesions, most likely DSBs, eliciting a cell death response 
(Branch et al., 1993).  
Whereas a significant percentage of gliomas lack expression of MGMT, due to 
hypermethylation of the MGMT promoter, whereas at least half of glioblastomas 
multiforme (GBM) express MGMT, its expression being associated with resistance to 
chemotherapy and poor prognosis (Hegi et al., 2005; Pollack et al., 2006). Strategies to target 
the MMR pathway and to improve the efficacy of TMZ to overcome resistance resulting 
from MGMT activity have been implemented. Ironically, somatic mutations-induced loss of 
function of MSH6 has also been associated with glioblastoma recurrence post irradiation 
and TMZ treatment (Cahill et al., 2007).  
In vitro, MGMT inhibitors such as O6-benzylguanine (O6-BG) can effectively overcome TMZ 
resistance in MMR-proficient cells, but revealed clinically ineffective (McMurry, 2007; 
Tentori et al., 1995). A viable option has been to target the BER pathway, which repairs the 
N7-methylguanine and N3-methyladenine lesions induced by TMZ. Pharmacological 
inhibition of this pathway resulted in TMZ-induced cytotoxicity enhancement, 
independently of MGMT status (Adhikari et al., 2008).  
5.2.3 Targeting simultaneously DNA and BER  
Tumors’ TMZ resistance strategies have been ascribed to elevated levels of MGMT and/or 
reduced MMR. Yet, recent data on human gliomas attributed a minor role to MMR 
deficiency and suggested the existence of other mechanisms (Maxwell et al., 2008). The 
involvement of BER seems very probable, since more than 80% of the DNA lesions induced 
by TMZ are recognized and processed by BER DNA glycosylases, independently of the 
MMR status (Liu & Gerson, 2004). BER glycosylases can lead to antimetabolite drug 
resistance by processing antimetabolite-DNA base damage (Cortellino et al., 2003; Jurado et 
al., 2004; Morgan et al., 2007). In TMZ-induced base damage, the repair process starts with 
the recognition and removal of the damaged bases by N-methylpurine DNA glycosylase 
(MPG), also known as alkyladenine DNA glycosylase (AAG). The resultant AP is then 
hydrolyzed by apurinic/apyrimidinic (AP) endonuclease 1 (APE1) (Almeida & Sobol, 
2007b). Enhanced sensitivity to alkylating agents upon modulation of the BER pathway has 
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recently been observed in preclinical studies (Kinsella, 2009). BER proteins as potential 
targets for chemotherapy sensitization are actually a field of active research.  
5.2.3.1 Targeting APE1  
The tumor microenvironment is characterized by acute/chronic hypoxia, low extracellular 
pH and nutrient access, affecting genomic stability (Reynolds et al., 1996), local progression, 
metastatic potential and response to radio- and chemotherapy (Overgaard, 2007). Multiple 
DNA repair systems are inhibited under hypoxic and/or low pH extracellular conditions, 
including MMR (Koshiji et al., 2005), NER (Yuan et al., 2000) and HR (Bindra et al., 2004).  
In stark contrast, APE1 was found to have greater activity in various types of tumors 
compared with normal tissues (Yoo et al., 2008). Potent direct inhibitors of APE1 have been 
identified, such as arylstibonic acid derivatives (Seiple et al., 2008), which are being 
developed to sensitize cancer cells against other DNA damaging agents; however, it was 
reported that the APE1 inhibitor 7-nitroindole-2-carboxylic acid increases DNA oxidative 
damage, DSBs and cell death in the acidic tumor microenvironment (Horton & Wilson, 
2007). Methoxyamine (MX) is a small molecule being evaluated in conjunction with TMZ in 
phase I clinical trials that specifically binds to and modifies AP sites, making them refractory 
to APE1 and highly cytotoxic, preventing their processing by BER ensuing steps (Yan et al., 
2007). Therefore, MX potentiates the action of AP sites-producing agents, regardless of 
MMR, MGMT or Tp53 status (Liu et al., 1999).  
5.2.3.2 Small molecular weight inhibitors of SN-BER and LP-BER 
An emerging concept in cancer therapy is the sensitization of cancer cells to DNA-damaging 
agents by inhibiting various proteins in the DNA repair pathways. Small molecular weight 
inhibitors (SMIs) have been used to target the BER pathway by inhibiting APE1 and Polǃ 
activities. Several Polǃ inhibitors have been reported in recent years (Horton & Wilson, 2007). 
Pamoic acid is the most active inhibitor of Polǃ (Hu et al., 2004), blocking just Polǃ-directed 
SN-BER only at high concentrations. As LP-BER can also repair abasic DNA sites, new agents 
that specifically block both Polǃ-directed SN- and LP-BER pathways are being tested, as there 
is a protein, APC, that interacts with Polǃ and FEN1, blocking both SN- and LP-BER pathways 
(Jaiswal & Narayan, 2008; Kundu et al., 2007). Recently, two other potent SMIs, NSC-666715 [4-
chloro-N-(3-(4-chloroanilino)-1H-1,2,4-triazol-5-yl)-2-mercapto-5-methylbenzenesulfonamide] 
and NSC-124854 [5-(4-amino-6-iodo-2-oxo-5,6-dihydropyrimidin-1-yl)-3-hydroxy-oxolan-2-yl] 
methoxyphosphonic acid, that interact with Polǃ, blocking simultaneously SN- and LP-BER 
activities, without blocking neither APE1, FEN1 nor DNA ligase IV activities, were reported to 
enhance TMZ efficiency both in vitro and in vivo (Jaiswal et al., 2011; Jaiswal et al., 2009). 
5.2.3.3 Inhibitors of PARP I and PARG 
PARP I is an abundant nuclear enzyme that senses both SSBs and DSBs and functions in 
both SN- and LP- BER. In BER, PARP I acts as a nick sensor, catalyzing the addition of ADP-
ribose units to DNA, histones and other target proteins: negatively charged ADP-ribose 
polymers then create electrostatic repulsions between DNA and histones, opening the 
chromatin for DNA repair. PARP I also recruits BER proteins to sites of single-stranded 
DNA breaks, initiating DNA repair (Ratnam & Low, 2007). PARP I expression/activity 
increases significantly in human normal and cancer cell lines after exposure to 
monofunctional and bifunctional alkylating agents, topoisomerase I inhibitors such as 
irinotecan, antimetabolites, including gemcitabine, as well as ionizing radiation (Ratnam & 
Low, 2007). High PARP I levels were also found in a variety of human cancers (Ratnam & 
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Low, 2007), being commonly associated with drug resistance and overall ability to survive 
genotoxic stress (Shiobara et al., 2001). As PARP I knockdown mice are hypersensitive to 
ionizing radiation and alkylating agents (de Murcia et al., 1997) and overexpression of 
dominant-negative PARP I in nude mice results in tumor cell apoptosis (Hans et al., 1999), 
PARP I inhibition offers the opportunity to enhance chemotherapeutic- and ionizing 
radiation–mediated cytotoxicity in human cancers. In fact, PARP I inhibitors, in preclinical 
and clinical development for several decades, overcome TMZ resistance (Liu et al., 1999) and 
enhance oxaliplatin efficacy in vitro and in vivo (Melisi et al., 2009), while protecting against 
side effects of some anticancer drugs, such as doxorubicin (Pacher et al., 2002).  
PARG is the main enzyme that targets poly ADP-ribose (PAR) for degradation via endo- 
and exoglycosidic cleavage (Hassa et al., 2006). Albeit PARG null mutations are embryonic 
lethal (Cortes et al., 2004), a PARG inhibitor, GPI 16552, has been shown to chemosensitize 
malignant melanoma to TMZ (Tentori et al., 2005). The same effect has been achieved by 
shRNA-mediated PARG knockdown in glioma cells (Tang et al., 2011). 
5.2.4 Therapies targeting simultaneously DNA and HR/NHEJ 
5.2.4.1 Targeting DNA-PKcs  
DSBs are induced by radiation and anticancer drugs such as cyclophosphamide, cisplatin, 
doxorubicin or etoposide (Barcellos-Hoff et al., 2005; Christmann et al., 2003). NHEJ is 
involved in DSB repair and does not depend on the presence of homologous DNA 
sequences (section 4) and requires the DNA-PKcs and one of its targets, the XRCC4/DNA-
ligase IV complex (Lieber, 1999). Importantly, the catalytic subunit of DNA-PK, DNA-PKcs, 
phosphorylates itself, other repair proteins and Tp53 (Smith & Jackson, 1999). An inverse 
correlation between the level of DNA‐PKcs and radiation sensitivity exists in human 
tumors: it was demonstrated that mutant cells radiosensitivity could be rescued by 
introduction of functional, but not kinase activity-deficient, DNA‐PKcs cDNA, showing that 
DNA-PKcs kinase activity is essential for DNA repair (Kurimasa et al., 1999). The binding of 
DNA‐PKcs to DNA ends (Lieber, 1999), together with the ability to phosphorylate a variety 
of nuclear targets (Smith & Jackson, 1999), may determine whether a break is repaired by 
NHEJ, redirected for repair by an alternative pathway or left unrepaired, potentially leading 
to irreversible growth arrest or cell death. Therefore, induction of DNA‐PKcs complex 
arrestment at the DNA termini is potentially more effective in radiosensitizing tumor cells 
than reducing DNA‐PKcs expression itself, as the presence of a non‐functional repair 
complex may block access to proteins from other DSB repair systems, leading to chronically 
unrepaired damage.  
The first approach to inhibit DNA-PKcs in vitro and in vivo used rather unspecific 
pharmacological inhibitors that also inhibited ATM and ATR, such as wortmannin (Sarkaria 
et al., 1998). More recently, 4’-bromo-3’-nitropropiophenone (NS-123) was shown to be more 
specific, enhancing, in vitro and in vivo, the cytotoxicity of biologically relevant doses of 
ionizing radiation, without any measurable normal tissue toxicity (Lally et al., 2007). The use 
of monoclonal antibodies, immunotoxins and radioimmunoconjugates to ameliorate chemo- 
and radiotherapy results has emerged as a promising strategy (Milas et al., 2005). A well-
tolerated and effective radioimmunotherapy option for patients with high-risk leukemia 
uses ǃ-emitting nuclides and antibodies (Kotzerke et al., 2005). Nevertheless, the use of ǂ-
particles can achieve higher biological effectiveness and more specific tumor cell killing with 
less damage to surrounding normal tissues, due to their short path length (50-80 µm) and 
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high energy transfer of α-particles emitting radioisotopes compared with ǃ-emitters and 
external radiation, being ideal to eliminate residual or micrometastatic disease (Zalutsky & 
Pozzi, 2004).  
ǃ- and Ǆ-irradiation-induced DNA damage activate apoptotic pathways involving CD95 
ligand receptor–driven and the mitochondrial pathways (Friesen et al., 2003). In contrast, ǂ-
irradiation-induced DSBs activate the mitochondrial apoptotic pathway independently of 
CD95 receptor/ligand interactions in leukemia cells. However, NHEJ inhibits doxorubicin-, 
Ǆ-irradiation and ǃ-irradiation–induced apoptosis, shedding light on why defective 
apoptosis signaling or increased DNA repair ability are involved in cross-resistance between 
radio- and chemotherapy (Friesen et al., 2003). In order to override cross-resistance against 
ǃ-irradiation, Ǆ-irradiation, doxorubicin and radioactive [213Bi]anti-CD45 has been 
successfully used recently: in the case of doxorubicin, it overcame NHEJ, possibly by 
decreasing DNA-PKcs or DNA-ligase IV activities, leading to efficient caspase activation 
and concomitant apoptosis (Friesen et al., 2008).  
5.2.4.2 Targeting Ku70 
Hypoxic regions exist in many human cancers, and hypoxia-induced radioresistance has 
been postulated as an obstacle in achieving local control in tumors with a sizable hypoxic 
fraction. Even so, radioresistant tumor cells could be sensitized by modulating the cellular 
level/activity of Ku/DNA-PKcs and adjuvant strategies can be developed for targeted 
radiotherapy. Accordingly, a DNKu70 construct, designed based on the analysis of the 
structure-function of Ku70 and on the crystal structure of Ku70/Ku80 heterodimer, induced 
a decrease in Ku-DNA end-binding activity, and the persistence of Ǆ-H2AX foci increased 
the radiosensitivity of infected human glioma U-87 MG cells and human colorectal tumor 
HCT-8 cells, both under aerobic and hypoxic conditions (He et al., 2007).  
In solid tumors, the tolerance of surrounding tissues often limits the dose of radiation that 
can be delivered. In gliomas, for instance, a recent prospective clinical trial found that 
radiotherapy combined with TMZ significantly improves patient’s survival (Stupp et al., 
2005). Unsuccessful attempts have been made at increasing the radiation dose, either with 
additional external beam radiotherapy, brachytherapy or stereotactic radiosurgery (Chan et 
al., 2002b; Regine et al., 2000; Tatter et al., 2003). 
5.2.4.3 Targeting RAD51 
Given the role of DNA repair in the radioresponse of human tumor cells, particularly of the 
DNA-PK-dependent NHEJ and HR systems, several strategies address either DNA-PK or 
RAD51. In the particular case of high grade gliomas, tumors that are strongly resistant and 
characterized by RAD51-mediated DNA repair activity, the in vitro cytotoxicity to combined 
TMZ and radiotherapies was achieved by suppressing the expression of RAD51 (Short et al., 
2011). Alternatively, in NSCLC cell lines, radiosensitization was achieved using antisense 
oligodeoxynucleotide, specifically targeting RAD51 mRNA, or wortmannin, a well-known 
inhibitor of NHEJ that also inhibits RAD51 foci formation (Sak et al., 2005). 
5-Iodo-2’-deoxyuridine (IUdR), a halogenated thymidine analogue, has been long 
recognized as an in vitro/in vivo radiosensitizer (Kinsella, 1996). The levels of thymidine 
replacement by IUdR in DNA, enhanced by caffeine and caffeine–like drugs in Tp53-
deficient xenografts, directly correlate with the extent of radiosensitization (Seo et al., 2006). 
This radiosensitization is ascribed to ionizing radiation–induced DNA strand breaks, most 
likely due to the generation of reactive free radicals from the IUdR incorporated into DNA. 
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As caffeine abrogates S- and G2-phase cell cycle arrests (Eastman, 2004), it can eventually be 
used to reduce DSB repair through the disruption of both ATR-CHK1-RAD51 and ATR-
CHK1-CDC25 pathways (Sorensen et al., 2005). Regrettably, IUdR is also incorporated into 
the DNA of rapidly proliferating normal tissue, resulting in myelosuppression and 
gastrointestinal toxicity. To circumvent this, 5-iodo-2-pyrimidinone-2’-deoxyribose (IPdR), 
an IUdR derivative, has recently been developed. Its low systemic toxicity and rapid liver 
conversion into IUdR renders this pro-drug quite useful in the treatment of tumors 
surrounded by non-proliferating normal tissues. That is the case of primary and metastatic 
brain and liver tumors and high-grade sarcomas (Kinsella et al., 2007). 
5.2.4.4 Targeting XRCC4/ DNA ligase IV  
Given the plethora of potential targets within the NHEJ group of proteins, it is worth 
mentioning some potential advantages and disadvantages of targeting XRCC4/DNA ligase 
IV. One of these advantages resides in the fact that DNA ligase IV is apparently distinct 
from other DNA ligases and its relationship with XRCC4 and DNA repair seems unique. 
This may unveil specificity or, conversely, decrease efficacy. It is also possible that, by virtue 
of its low abundance and potential rate-limiting nature, XRCC4/DNA ligase IV may be a 
better target for intervention than DNA-PKcs or Ku proteins. Furthermore, cells lacking 
DNA ligase IV show considerably slower rejoining kinetics following irradiation than cells 
lacking DNA-PKcs or Artemis (a protein with major functions in V(D)J recombination and 
NHEJ). In addition, DNA ligase IV seems to be involved in all classes of breaks, unlike the 
other proteins, which may be more selective (Lobrich & Jeggo, 2005). Recently, adenovirus-
mediated expression of the XRCC4 fragment resulted in radiosensitization in breast cancer 
cells (Jones et al., 2005). One major drawback in clinic, even with intensity-modulated 
radiotherapy delivery, is that normal tissues will also be affected and, as such, careful 
monitoring is required.  
5.2.4.5 Targeting BMP1 
Ionizing radiation represents the most effective therapy for glioblastoma (World Health 
Organization grade IV glioma), one of the most lethal human malignancies. Yet, radiotherapy 
remains only palliative because of radioresistance. CD133-expressing (CD133+) tumor cells 
present in glioma have stem-like properties and, as such, are named neuronal cancer stem cells 
(NCSCs). NCSCs are major contributors to glioma radioresistance, through preferential 
activation of the DNA damage checkpoint response and an increase in DNA repair capacity. 
The efficient DNA damage response/repair and radioresistance of glioblastoma multiforme 
(GMB) was recently ascribed to the stem cell factor BMP1, present in high levels in CD133+ 
GBM cells (Facchino et al., 2010). BMP1 is a key component of multiprotein Polycomb 
repression complex 1, critical for the maintenance of chromosome integrity in both normal and 
transformed cells (Chagraouia et al., 2011). Cancer cells, including glioma, are very sensitive to 
genotoxic agents following BMP1 depletion, possibly by an acquired dependency upon BMP1 
anti-apoptotic activity through transcriptional (i.e., tumor suppressor genes repression) and 
non-transcriptional (i.e., HR and NHEJ proteins DNA-PK, PARP I) activities (Chagraouia et al., 
2011; Facchino et al., 2010). As the radioresistance of CD133+ glioma stem cells can be reversed 
with a specific inhibitor of the CHK1 and CHK2 checkpoint kinases, it is possible that an 
approach combining the cell’s preferential sensitivity to BMP1 depletion and inhibitors of 
checkpoint kinases could be exploited to specifically target NCSCs following radiotherapy 
(Bao et al., 2006). 
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5.2.5 Therapies targeting simultaneously DNA and NER repair system 
Activation of DNA repair mechanisms circumvents chemotherapeutic drug-induced DNA 
damage (Edwards et al., 2008), yet defects in those systems may also contribute to tumor 
drug resistance. In particular, impaired NER correlates with loss of susceptibility to cisplatin 
(Mountzios et al., 2008) and trabectedin (Von Mehren, 2007).  
Albeit enhancing NER protects against accumulation of DNA lesions and maintains 
genomic integrity, reducing the NER threshold may be beneficial for cancer patients 
undergoing chemotherapy to ensure the efficient action of DNA damage-inducing drugs 
(Liu et al., 2010). The newly identified circadian oscillation of XPA expression, coupled with 
a short half-life of the protein, hints that an optimal time window for treatment with drugs 
whose provoked DNA lesions elicit BER, such as cisplatin and other base damaging drugs, 
may be found. Actually, transient suppression of NER through chronochemotherapy 
manipulation of core NER factors or regulatory pathways is anticipated to synergize with 
DNA damaging agents to optimize the chemotherapeutic outcome (Kang & Sancar, 2009) 
5.2.6 Therapies addressed to MSI tumors 
The epigenetic silencing that occurs during tumor development deeply affects the response 
of tumors to chemotherapy (Teodoridis et al., 2005), as illustrated by the epigenetic 
inactivation of the MGMT gene and the consequent increase of gliomas’ resistance to 
monofunctional alkylating agents (Hegi et al., 2005). Another example is the relation 
between the epigenetic status of MLH1 protein and the sensitivity to a wide range of 
important chemotherapeutic agents (Gifford et al., 2004; Sargent et al., 2010). 
Patients with MSI stage II CRCs receiving 5FU treatment require adjuvant chemotherapy 
with oxaliplatin to override 5FU negative effects and, consequently, increase their survival 
(Kim et al., 2010). Other 5FU adjuvant therapies containing FU, irinotecan and leucovorin 
(folinic acid vitamin) were tested unsuccessfully (Van Cutsem et al., 2009). Another strategy 
based on the topoisomerase 1 (TOP1) inhibitor irinotecan evidenced that MSI tumors 
respond better to this drug than tumors with intact MMR (Jacob et al., 2001). The mechanism 
underlying this response is still not clear, but irinotecan, apparently, inhibits the catalytic 
function of TOP1 by stabilizing covalent complexes formed between DNA, prevents DNA 
from unwinding (Hsiang et al., 1989) and induces SSBs that are later converted into DSBs 
after replication fork collapse (Vamvakas et al., 1997). However, possibly it is not the MMR 
defect itself, but rather the loss of one or more of the genes associated to MSI, that causes the 
observed chemosensitivity. 
Ironically, epigenetic silencing can also be achieved during chemotherapy and may be an 
important driving force behind acquired drug resistance (Glasspool et al., 2006). In ovarian 
and peritoneal cancer patients, cisplatin and carboplatin/paclitaxel or carboplatin/docetaxel 
treatments were reported to induce MLH1 down-regulation or promoter hypermethylation 
and, consequently, MSI (Strathdee et al., 1999). Therefore, there is considerable interest in the 
association of epigenetic therapies with existing chemotherapeutic agents, to improve initial 
tumor response and to overcome acquired drug resistance. The use of the DNA 
hypomethylating agent decitabine (2-deoxy-5′azacytidine) resulted in partial reversal of 
DNA methylation of MLH1 and was reported to increase the sensitivity to cisplatin and 
carboplatin both in vitro and in vivo (Cameron et al., 1999). However, the dose limiting 
toxicity of decitabine (i.e., myelosuppression) plus the limited demethylation in tumors, 
coupled with the eventual re-methylation of genes, may limit the clinical use of decitabine in 
monotherapy of solid tumors. 
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5-Fluoro-2′-deoxycytidine (FdCyd) is a DNA methyltransferase inhibitor and a 
hypomethylating agent when incorporated into the DNA of exposed cells (Kaysen et al., 
1986). Indeed, to prevent re-methylation and re-silencing of genes, long-term exposures to 
DNA methylation inhibitors are needed, as are new strategies to use them. Manipulation of 
FdCyd metabolism using the cytidine deaminase inhibitor tetrahydrouridine (THU) 
enhanced the re-expression of MLH1, converting resistant hypermethylated MLH1- colon or 
ovarian cancer cells to sensitive 5FU cells, because they re-expressed functional MLH1 and 
therefore competent MMR (Beumer et al., 2008). Full exploitation of DNA methyltransferase 
inhibition may well need long-term exposure to low concentrations of the inhibitor, as 
observed with 5-azacytidine and 5-aza-2′-deoxycytidine (Lyko & Brown, 2005).  
Finally, the combination of a demethylating agent and, the histone deacetylase (HDAC) 
inhibitor, trichostatin A has recently been examined in clinical trials of hematological 
malignancies. By combining non-toxic doses of decitabine with the HDAC inhibitor 
belinostat, a marked increase in MLH1 expression both in vitro and in vivo was observed, as 
was a boost of cisplatin sensitivity in tumor xenografts (Steele et al., 2009). 
5.3 Modulating cancer therapies using mathematical models 
The overall complexity of DNA repair pathways is a major obstacle in designing and 
analyzing clinical trials using cancer-targeted treatment; probabilistic computational 
modeling is being used to better integrate chemotherapheutics and ionizing radiation-
induced damage. Recently, a stochastic model for cell cycle progression in two synchronized 
isogenic MMR-deficient (MMR-) and MMR-proficient (MMR+) CRC cells, treated or not with 
iododeoxyuridine (IUdR), was built, followed by a second model to obtain correlations 
between the percentage of cells in different cell cycle states and the corresponding IUdR-
DNA incorporation at particular time points. Combining both models could predict IUdR 
incorporation in DNA incorporation at any time in the cell cycle. Consequently, maximum 
benefit of the therapeutic action of IUdR treatment and radiation was achieved in xenografts 
MMR- tumors versus MMR+ normal tissues, before passing to clinical trials (Gurkan et al., 
2007). This suggests that the systems biology approach holds promise for strategies using 
chemo- and radiotherapy synergistically and to better comprehend the effect of DNA repair 
systems on them. 
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